<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006742.pub2" GROUP_ID="HTN" ID="305407052211282758" MERGED_FROM="" MODIFIED="2014-05-31 14:57:44 +0100" MODIFIED_BY="Ciprian Jauca" NOTES="&lt;p&gt;&lt;span modified=&quot;2012-06-21 21:48:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;Re: &lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:49:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;1 Summary of findings:&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-06-21 20:25:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;I think that it is &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:26:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;highly unlikely that a significant benefit in mortality has been missed with the 8000+ &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:27:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;primary prevention &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:26:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;subjects &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:27:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;with mild HBP since no benefit in mo&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:28:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;rtality was seen in the &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:28:25 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;Therapeutics Intitiative &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:29:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;(&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:28:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;n&amp;gt;23,000&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:29:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;,t&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:29:09 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;otal mortality&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:29:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;:&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:29:09 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; RR 0.95 [0.71 - 1.11]&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:29:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;)&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:30:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;, including subjects at significantly higher mortality risk. &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:32:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;A statistician could tell you the number of participants &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:33:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;in a future trial &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:32:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;required to demonstrate&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:33:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; a &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:35:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;mortality&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:33:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; RR of &amp;lt; 0.90. Based on the &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:34:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;Therapeutics initiative as well as the data in this review, I guess it would be &amp;gt; 100,000.&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:35:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:40:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;I think that a&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:37:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; trial of this size&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:38:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:39:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;of&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:38:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; mild hypertension patients &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:40:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;c&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:38:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;ould be put to better use than c&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:39:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;onfirming &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:40:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;what is&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:41:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; already&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:40:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; overwhel&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:41:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;mingly probable &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:39:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;that there is no mortality benefit with the same drugs used in the previous trials.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-06-21 20:44:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;B&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:45:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;efore advocating for&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:44:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; more RCTs to show&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:45:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; a reduction in total CV events, I think &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:46:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;that a statistician should assess n&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:47:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;umber of subjects required&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:48:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; to show&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:49:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; an RR &amp;lt; 0.90 and an RR &amp;lt; 0.80&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:51:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;, especially since we found it likely that the RRs in this review overestimated any benefit. A&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:52:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;dditionally, before considering further trials of drugs for mild HBP&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:53:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; in primary prevention patients, we should have data on deaths of primary preventio&lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:54:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;n patients from ACE inhibitors (i.e., angioedema) and other drugs. &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:58:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;HBP drug researchers would be put in the position of explaining to future trial subjects that &lt;/span&gt;&lt;span modified=&quot;2012-06-21 20:59:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;HBP drugs carry a small but finite risk of death and that past studies showed no re&lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:00:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;duction overall in CV events. &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-06-21 21:00:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-06-22 21:55:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;Changing the protocol for new drugs trials for mild HBP with prece&lt;/span&gt;&lt;span modified=&quot;2012-06-22 21:56:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;ding diet or diet and lifestyle interventions and measures to exclude pre hypertension patients would make future trial&lt;/span&gt;&lt;span modified=&quot;2012-06-22 21:57:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;s more worthy of consideration. &lt;/span&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-05-31 06:55:04 -0700" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="A056" REVMAN_SUB_VERSION="5.2.11 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2014-05-31 14:57:44 +0100" MODIFIED_BY="Ciprian Jauca">
<TITLE MODIFIED="2012-02-14 15:39:45 -0800" MODIFIED_BY="James M Wright">Pharmacotherapy for mild hypertension</TITLE>
<CONTACT MODIFIED="2014-05-31 14:57:44 +0100" MODIFIED_BY="Ciprian Jauca"><PERSON ID="C6C6EA3F82E26AA201E4B53D14EA83B9" ROLE="AUTHOR"><FIRST_NAME>Diana</FIRST_NAME><LAST_NAME>Diao</LAST_NAME><POSITION>Resident Physician</POSITION><EMAIL_1>dianadiao@gmail.com</EMAIL_1><MOBILE_PHONE>778-679-7424</MOBILE_PHONE><ADDRESS><DEPARTMENT>Postgraduate Education, Faculty of Medicine</DEPARTMENT><ORGANISATION>University of British Columbia</ORGANISATION><ADDRESS_1>Gordon and Leslie Diamond Health Care Centre</ADDRESS_1><ADDRESS_2>11th Floor - 2775 Laurel Street</ADDRESS_2><CITY>Vancouver</CITY><ZIP>V5Z 1M9</ZIP><REGION>BC</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-05-31 14:57:44 +0100" MODIFIED_BY="Ciprian Jauca"><PERSON ID="C6C6EA3F82E26AA201E4B53D14EA83B9" ROLE="AUTHOR"><FIRST_NAME>Diana</FIRST_NAME><LAST_NAME>Diao</LAST_NAME><POSITION>Resident Physician</POSITION><EMAIL_1>dianadiao@gmail.com</EMAIL_1><MOBILE_PHONE>778-679-7424</MOBILE_PHONE><ADDRESS><DEPARTMENT>Postgraduate Education, Faculty of Medicine</DEPARTMENT><ORGANISATION>University of British Columbia</ORGANISATION><ADDRESS_1>Gordon and Leslie Diamond Health Care Centre</ADDRESS_1><ADDRESS_2>11th Floor - 2775 Laurel Street</ADDRESS_2><CITY>Vancouver</CITY><ZIP>V5Z 1M9</ZIP><REGION>BC</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="5489" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>James</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Wright</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>jim.wright@ti.ubc.ca</EMAIL_1><URL>http://hypertension.cochrane.org/James-Wright</URL><ADDRESS><DEPARTMENT>Department of Anesthesiology, Pharmacology and Therapeutics</DEPARTMENT><ORGANISATION>University of British Columbia</ORGANISATION><ADDRESS_1>2176 Health Sciences Mall</ADDRESS_1><CITY>Vancouver</CITY><ZIP>V6T 1Z3</ZIP><REGION>BC</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1-604-822-4270</PHONE_1><PHONE_2>+1-604-822-0700</PHONE_2><FAX_1>+1-604-822-0701</FAX_1></ADDRESS></PERSON><PERSON ID="15725" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>Cundiff</LAST_NAME><POSITION>Attending Physician</POSITION><EMAIL_1>dkcundiff@thehealtheconomy.com</EMAIL_1><ADDRESS><DEPARTMENT>Internal Medicine</DEPARTMENT><ORGANISATION>LA County+USC Med Center (Retired)</ORGANISATION><ADDRESS_1>333 Orizaba Avenue</ADDRESS_1><CITY>Long Beach</CITY><ZIP>90814</ZIP><REGION>CA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 562 4388805</PHONE_1><FAX_1>+1 562 4334809</FAX_1></ADDRESS></PERSON><PERSON ID="5749" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Francois</FIRST_NAME><LAST_NAME>Gueyffier</LAST_NAME><EMAIL_1>francois.gueyffier@univ-lyon1.fr</EMAIL_1><ADDRESS><DEPARTMENT>UMR5558, CNRS et Université Claude Bernard - Service de Pharmacologie Clinique et Essais Thérapeutiques</DEPARTMENT><ORGANISATION>Hopital Cardio-Vasculaire et Pneumologique Louis Pradel</ORGANISATION><CITY>Lyon</CITY><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>00 33 (0)4 72 35 72 31</PHONE_1><FAX_1>00 33 (0)4 72 35 73 64</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-05-31 06:55:04 -0700" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="1" MONTH="10" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="10" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="9" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="8" YEAR="2012"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2012"/>
</DATES>
<WHATS_NEW MODIFIED="2014-05-31 06:54:27 -0700" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2014-05-31 06:54:27 -0700" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="12" YEAR="2013"/>
<DESCRIPTION>
<P>Comment: The results of this review should be interpreted (appropriately) as subgroup analyses</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-11-15 14:47:42 -0800" MODIFIED_BY="Ciprian Jauca">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2013-11-15 14:47:42 -0800" MODIFIED_BY="Ciprian D Jauca">
<DATE DAY="12" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>Comment: Should mild hypertension be treated?</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-02-07 16:31:10 -0800" MODIFIED_BY="James M Wright">
<INTERNAL_SOURCES MODIFIED="2012-02-07 16:31:10 -0800" MODIFIED_BY="James M Wright">
<SOURCE>
<NAME>Department of Anesthesiology, Pharmacology &amp; Therapeutics, University of British Columbia</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-02-07 16:24:10 -0800" MODIFIED_BY="James M Wright">
<NAME>Clinical Pharmacology Department, Hospices Civils de Lyon</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-02-07 16:25:57 -0800" MODIFIED_BY="James M Wright">
<NAME>UMR5558, CNRS</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-02-07 16:26:57 -0800" MODIFIED_BY="James M Wright">
<NAME>Claude Bernard University Lyon I</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-02-07 16:31:10 -0800" MODIFIED_BY="James M Wright">
<NAME>BIMBO project, SYSCOMM 2008 Nr 002, ANR- www.agence-nationale-recherche.fr</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>CIHR Grant to the Hypertension Review Group</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>British Columbia Ministry of Health Grant to the Therapeutics Initiative</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-10-17 17:51:57 -0700" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-07-09 21:08:07 -0700" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-09-27 19:56:08 -0700" MODIFIED_BY="[Empty name]">Benefits of antihypertensive drugs for mild hypertension are unclear</TITLE>
<SUMMARY_BODY MODIFIED="2012-07-09 21:08:07 -0700" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Regarding: &lt;b&gt;Plain Language Summary:&lt;br&gt;&lt;/b&gt;&amp;quot; Healthy individuals with mildly elevated blood pressures, but no previous hypertension-related cardiovascular events...&amp;quot;&lt;br&gt;You should not use the term 'healthy'. In fact they are referring to primary prevention patients, as defined. These people may or may not be 'healthy' whatever that means. &amp;quot;Healthy&amp;quot; is used throughout the review, please revise accordingly.&lt;br&gt;Later in the above sentence the authors refer to &amp;quot;hypertension-related CV events&amp;quot; which is not the definition of primary prevention.&amp;#160;Please revise accordingly.&amp;#160;&lt;/p&gt;&lt;p&gt;I agree to strike &amp;quot;healthy&amp;quot; throughout. However, I think it is important to retain, &amp;quot;but no previous hypertension-related cardiovascular events...&amp;quot; to differentiate stage 1 HBP with and without diagnosed CVD. Our review is of HBP patients without CVD diagnosed--primary prevention candidates. Our question is whether drugs should be added to diet, exercise, etc. as an additional primary prevention modality for stage 1 HBP. I don't understand how they want us to change this phrase. &lt;/p&gt;" NOTES_MODIFIED="2012-07-09 21:08:07 -0700" NOTES_MODIFIED_BY="[Empty name]">
<P>Individuals with mildly elevated blood pressures, but no previous cardiovascular events, make up the majority of those considered for and receiving antihypertensive therapy. The decision to treat this population has important consequences for both the patients (e.g. adverse drug effects, lifetime of drug therapy, cost of treatment, etc.) and any third party payer (e.g. high cost of drugs, physician services, laboratory tests, etc.). In this review, existing evidence comparing the health outcomes between treated and untreated individuals are summarized. Available data from the limited number of available trials and participants showed no difference between treated and untreated individuals in heart attack, stroke, and death. About 9% of patients treated with drugs discontinued treatment due to adverse effects. Therefore, the benefits and harms of antihypertensive drug therapy in this population need to be investigated by further research.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-10-17 17:43:47 -0700" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-07-09 21:02:04 -0700" MODIFIED_BY="[Empty name]">
<P>People with no previous cardiovascular events or cardiovascular disease represent a primary prevention population. The benefits and harms of treating mild hypertension in primary prevention patients are not known at present. This review examines the existing randomised controlled trial (RCT) evidence.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-03-15 18:10:42 -0700" MODIFIED_BY="[Empty name]">
<P>Primary objective: To quantify the effects of antihypertensive drug therapy on mortality and morbidity in adults with mild hypertension (systolic blood pressure (BP) 140-159 mmHg and/or diastolic BP 90-99 mmHg) and without cardiovascular disease.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-10-17 17:43:47 -0700" MODIFIED_BY="[Empty name]">
<P>We searched The Cochrane Central Register of Controlled Trials (CENTRAL) 2013 Issue 9, MEDLINE (1946 to October 2013), EMBASE (1974 to October 2013), ClinicalTrials.gov (all dates to October 2013), and reference lists of articles. The Cochrane Database of Systematic Reviews and the Database of Abstracts of Reviews of Effectiveness (DARE) were searched for previous reviews and meta-analyses of anti-hypertensive drug treatment compared to placebo or no treatment trials until the end of 2011.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-02-14 15:43:03 -0800" MODIFIED_BY="[Empty name]">
<P>RCTs of at least 1 year duration.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-02-14 15:43:38 -0800" MODIFIED_BY="[Empty name]">
<P>The outcomes assessed were mortality, stroke, coronary heart disease (CHD), total cardiovascular events (CVS), and withdrawals due to adverse effects.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-10-17 16:34:21 -0700" MODIFIED_BY="[Empty name]">
<P>Of 11 RCTs identified 4 were included in this review, with 8,912 participants. Treatment for 4 to 5 years with antihypertensive drugs as compared to placebo did not reduce total mortality (RR 0.85, 95% CI 0.63, 1.15). In 7,080 participants treatment with antihypertensive drugs as compared to placebo did not reduce coronary heart disease (RR 1.12, 95% CI 0.80, 1.57), stroke (RR 0.51, 95% CI 0.24, 1.08), or total cardiovascular events (RR 0.97, 95% CI 0.72, 1.32). Withdrawals due to adverse effects were increased by drug therapy (RR 4.80, 95%CI 4.14, 5.57), Absolute risk increase (ARI) 9%.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-03-15 18:11:11 -0700" MODIFIED_BY="[Empty name]">
<P>Antihypertensive drugs used in the treatment of adults (primary prevention) with mild hypertension (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) have not been shown to reduce mortality or morbidity in RCTs. Treatment caused 9% of patients to discontinue treatment due to adverse effects. More RCTs are needed in this prevalent population to know whether the benefits of treatment exceed the harms.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-10-17 17:51:57 -0700" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-07-09 21:16:03 -0700" MODIFIED_BY="James M Wright">
<P>Previous meta-analyses have concluded that cardiovascular events and overall mortality are decreased with antihypertensive drug therapy as compared to placebo or no treatment (<LINK REF="REF-Collins-1990" TYPE="REFERENCE">Collins 1990</LINK>, <LINK REF="REF-Gueyffier-1996" TYPE="REFERENCE">Gueyffier 1996</LINK>, <LINK REF="REF-Psaty-1997" TYPE="REFERENCE">Psaty 1997</LINK>, <LINK REF="REF-Wright-1999" TYPE="REFERENCE">Wright 1999</LINK>, <LINK REF="REF-Quan-2000" TYPE="REFERENCE">Quan 2000</LINK>, <LINK REF="REF-Psaty-2003" TYPE="REFERENCE">Psaty 2003</LINK>, <LINK REF="REF-Wright-2009" TYPE="REFERENCE">Wright 2009</LINK>). These meta-analyses have combined subjects with mild elevations of blood pressure (stage 1), 140-159/ 90-99 mmHg, and moderate to severe elevations of blood pressure (&gt; 160/100 mmHg). These meta-analyses have also combined patients who have had a previous cardiovascular event (secondary prevention) with subjects who have not had a cardiovascular event (primary prevention). It is commonly assumed that the treatment effect expressed as relative risk is the same for primary prevention and secondary prevention populations; however, this is not proven. Furthermore, it is expected that the absolute risk reduction would be larger in secondary prevention populations than in primary prevention populations.</P>
<P>At the present time, individuals with mild elevations of blood pressure and no cardiovascular disease (primary prevention) are commonly treated with antihypertensive drugs despite there being no direct evidence supporting this practice. Furthermore this represents about half of the people presently being treated with antihypertensive drugs since the proportion of patients with mild elevations in blood pressure is about the same as the proportion with moderate to severe elevations in blood pressure (<LINK REF="REF-Marchant-2011" TYPE="REFERENCE">Marchant 2011</LINK>). Therefore it is evident that there is a need to determine whether there is a proven reduction in mortality and morbidity with antihypertensive treatment in this patient group and if so the magnitude of that reduction. An attempt to do this by limiting to trials where patients were categorized as mild hypertension has been done (<LINK REF="REF-Therapeutics-Initiative-2007" TYPE="REFERENCE">Therapeutics Initiative 2007</LINK>), however in that analysis the average blood pressure at baseline was 160/98 mmHg, making it clear that even in that attempt about half of the individuals had moderate elevations of blood pressure at baseline. In that analysis antihypertensive treatment reduced total cardiovascular events, but not mortality. However, the findings of that analysis cannot be assumed to be extrapolated to the patients (about half of the total) that had mild elevations of blood pressure at baseline. The objective of this review was to assess the mortality and morbidity outcomes in randomized controlled trials using individual patient data whenever possible and limit the analysis to a primary prevention population with mild elevations of blood pressure at baseline.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-02-09 18:15:16 -0800" MODIFIED_BY="[Empty name]">
<P>1. To quantify the effects of antihypertensive drug therapy as compared to no treatment on mortality and morbidity in healthy adults with mild elevations of blood pressure (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg).</P>
<P>2. To quantify withdrawals due to adverse drug effects for antihypertensive drug therapy in healthy adults with mild hypertension.<BR/>
</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-10-17 17:51:57 -0700" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-07-09 22:19:38 -0700" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised controlled trials of at least 1 year duration.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-07-09 22:19:38 -0700" MODIFIED_BY="James M Wright">
<P>A primary prevention population of men and non-pregnant women, greater than 18 years of age with mild hypertension defined as a systolic blood pressure of 140 - 159 mmHg or diastolic blood pressure 90 - 99 mmHg and no evidence of cardiovascular disease at baseline: specifically defined as no myocardial infarction (MI), angina pectoris, coronary bypass surgery, coronary angioplasty, stroke, transient ischaemic attack, carotid endarterectomy, surgery for peripheral vascular disease, intermittent claudication, or renal failure (creatinine &gt; 1.5 times the upper limit of normal). More than 80% of patients in a trial had to have mild hypertension as defined above for the trial to be included unless individual patient data was available allowing specific inclusion of this population as defined.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-10-20 06:31:13 -0700" MODIFIED_BY="[Empty name]">
<P>Treatment with an antihypertensive drug either as monotherapy or with the addition of other drugs in a stepped care approach. Control: placebo or no antihypertensive treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-07-09 21:24:50 -0700" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-07-09 21:23:23 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>Total mortality<BR/>Total cardiovascular events (total stroke, total MI and total congestive heart failure CHF)</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-07-09 21:24:34 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>Total stroke (fatal and nonfatal strokes)<BR/>Total coronary heart disease (fatal and non-fatal myocardial infarction, sudden death)</P>
<P>Withdrawals due to adverse drug effects</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-10-17 17:51:57 -0700" MODIFIED_BY="[Empty name]">
<P>The Database of Abstracts of Reviews of Effectiveness (DARE) and the Cochrane Database of Systematic Reviews were searched to the end of 2011 for related reviews and meta-analyses of anti-hypertensive drug treatment compared to placebo or no treatment trials. Reports of relevant trials referred to in these reviews were obtained.</P>
<P>The following electronic databases were searched for primary studies: CENTRAL (2013, Issue 9), MEDLINE (1946 to October 2013), EMBASE (1974 to October 2013), ClinicalTrials.gov (all dates to October 2013), and reference lists of articles.</P>
<P>Electronic databases were searched using a strategy combining the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision) with selected MeSH terms and free text terms relating to hypertension. No language restrictions were used. The MEDLINE search strategy (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) was translated into EMBASE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), CENTRAL (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), and Clinical Trials.gov (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>) using the appropriate controlled vocabulary as applicable.</P>
<P>Other sources:</P>
<P>a)    Reference lists of all papers and relevant reviews identified</P>
<P>b)    Authors of relevant papers were contacted regarding any further published or unpublished work</P>
<P>c)    Authors of trials reporting incomplete information were contacted to provide the missing information</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-07-09 22:20:05 -0700" MODIFIED_BY="James M Wright">
<P>All abstracts of trials identified by electronic searching or bibliographic scanning were screened. Those studies which appeared to meet the predetermined inclusion criteria stated above were selected on the basis of full text screening. When some trials also included subjects different than those of interest e.g.. secondary prevention, stage 2 hypertension, we attempted to get the data on the subjects with mild hypertension as defined in this review. Such information was available for a large number of subjects in the INDANA database primarily from the Australian trial (<LINK REF="STD-ANBP" TYPE="STUDY">ANBP</LINK>) in mild hypertension and the <LINK REF="STD-MRC" TYPE="STUDY">MRC</LINK> trial in mild hypertension. Despite all efforts individual subject data were not available for the <LINK REF="STD-Oslo" TYPE="STUDY">Oslo</LINK> study, the <LINK REF="STD-USPHSHC" TYPE="STUDY">USPHSHC</LINK> study, and the <LINK REF="STD-VA_x002d_NHLBI" TYPE="STUDY">VA-NHLBI</LINK> study. Data abstraction was undertaken by 2 independent reviewers who collected information on the following characteristics for each trial: type and dose of antihypertensive drugs used; other interventions used; patient characteristics, including co-morbid conditions; morbidity and mortality outcomes; and length of trial follow-up.</P>
<P>Risk of bias was also assessed independently by 2 reviewers using the risk of bias tool and the following criteria: sequence generation, allocation concealment, blinding, Incomplete outcome data, selective reporting or other biases. Disagreements between independent reviewers arising in any of the stages above were resolved by a third reviewer (JMW).</P>
<P>Using the Cochrane software (RevMan) a quantitative analysis was carried out based on the availability of outcome data in the defined population. Individual patient data from 3 trials (<LINK REF="STD-ANBP" TYPE="STUDY">ANBP</LINK>; <LINK REF="STD-MRC" TYPE="STUDY">MRC</LINK>; <LINK REF="STD-SHEP" TYPE="STUDY">SHEP</LINK>) and all data from 1 trial (<LINK REF="STD-VA_x002d_NHLBI" TYPE="STUDY">VA-NHLBI</LINK>) were pooled. Meta-analysis was performed using the Mantel-Haenszel statistical method and a fixed effects model. The risk ratio of each outcome comparing treatment versus no treatment or placebo was calculated.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-07-09 22:20:11 -0700" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-07-09 21:36:31 -0700" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>We retrieved 11 studies where antihypertensive therapy was administered for primary prevention in subjects with mild hypertension, published between 1966 and 2005 (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We excluded 2 trials because they had 2 or fewer subjects who met the criteria outlined in this review (<LINK REF="STD-MRC2" TYPE="STUDY">MRC2</LINK>, <LINK REF="STD-COOPE" TYPE="STUDY">COOPE</LINK>) and 3 trials because they did not have a placebo or no-treatment study group (<LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>, <LINK REF="STD-MRFIT" TYPE="STUDY">MRFIT</LINK>, <LINK REF="STD-FEVER-2005" TYPE="STUDY">FEVER 2005</LINK>). Despite considerable effort we were unable to obtain individual subject data for the <LINK REF="STD-Oslo" TYPE="STUDY">Oslo</LINK>, <LINK REF="STD-USPHSHC" TYPE="STUDY">USPHSHC</LINK>, and <LINK REF="STD-VA_x002d_NHLBI" TYPE="STUDY">VA-NHLBI</LINK> studies (2,186 patients). Based on the baseline blood pressure and standard deviation, we established that more than 20% of the patients in the <LINK REF="STD-Oslo" TYPE="STUDY">Oslo</LINK> Study and the <LINK REF="STD-USPHSHC" TYPE="STUDY">USPHSHC</LINK> study had moderately elevated blood pressure. Therefore these trials were excluded as they could not be expected to reflect the effects in a primary prevention population with mild hypertension. In the <LINK REF="STD-VA_x002d_NHLBI" TYPE="STUDY">VA-NHLBI</LINK> trial, less than 20% of subjects had moderately elevated blood pressure so we included this trial (1,012 patients). Individual subject data was obtained for <LINK REF="STD-ANBP" TYPE="STUDY">ANBP</LINK>, <LINK REF="STD-MRC" TYPE="STUDY">MRC</LINK>, and <LINK REF="STD-SHEP" TYPE="STUDY">SHEP</LINK> trials and only those subjects who met the above stated criteria at baseline were included in this review (7,900 patients).The characteristics of these 4 included trials (8912 participants) in this review are summarized in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-02-28 14:41:00 -0800" MODIFIED_BY="James M Wright">
<P>Risk of bias from 5 domains was assessed for each of the included studies (see <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-07-09 22:20:11 -0700" MODIFIED_BY="[Empty name]">
<P>For the 8912 participants included in this review, treatment with antihypertensive drugs as compared to no treatment did not reduce total mortality (RR 0.85, 95% CI 0.63, 1.15). Furthermore, antihypertensive treatment did not significantly reduce total stroke (RR 0.51, 95% CI 0.24, 1.08), total coronary heart disease (RR 1.12, 95% CI 0.80, 1.57) or total cardiovascular events (RR 0.97, 95% CI 0.72, 1.32) (see <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>).</P>
<P>Withdrawals due to adverse effects (WDAEs) was only available from all patients in the MRC trials and not from the subgroup of patients with mild hypertension. Assuming that withdrawals due to adverse effects would be similar in the participants with mild hypertension and those with moderate to severe hypertension, we have calculated this value for the whole trial. This showed an increase in WDAEs with antihypertensive treatment RR 4.80 [4.14, 5.17], ARR 8.9%. The <LINK REF="STD-VA_x002d_NHLBI" TYPE="STUDY">VA-NHLBI</LINK> trial reported any adverse symptom 1642/508 in the treatment group and 920/504 in the no treatment group. Chemical abnormalities such as hypokalaemia were also increased in the treatment group, 216 versus the control group, 15.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-07-09 22:20:16 -0700" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-07-09 21:53:02 -0700" MODIFIED_BY="[Empty name]">
<P>This review demonstrates that antihypertensive drugs used in the treatment of patients without a previous cardiovascular event (primary prevention) with mild hypertension (systolic BP 140-159 mmHg and / or diastolic BP 90-99 mmHg) have not been proven to significantly reduce any outcome including total mortality, total cardiovascular events, coronary heart disease, or stroke. This review provides data on &gt;8,000 people followed for 5 years and suggests little or no reduction in total cardiovascular events, RR 0.97 [0.72, 1.32] (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The review also shows a non-significant reduction in stroke, RR 0.51 [0.24, 1.08] and mortality 0.85 [0.63, 1.15] consistent with there being a real benefit of treatment, but that it wasn't demonstrable due to the paucity of events and people. Thus it remains possible, but highly unlikely, that there is an overall significant benefit of treating this group of patients with currently used medications.</P>
<P>However, even if the assumption is made, as is commonly done, that the relative benefits for a primary prevention population with mild hypertension are the same as for patients with moderate to severe hypertension, mortality RR 0.9 and total CV events RR 0.7 from the review of first-line treatments of hypertension (<LINK REF="REF-Wright-2009" TYPE="REFERENCE">Wright 2009</LINK>) then the absolute benefits would be very small. We have made this estimate from the placebo group in the largest trial in this review (<LINK REF="STD-MRC" TYPE="STUDY">MRC</LINK>). The estimated absolute risk reduction in this best case scenario is 0.25% for mortality and 0.78% for total cardiovascular events over a 5 year period. This means that 400 people would have to be treated for 5 years to prevent 1 death and 128 people would have to be treated for 5 years to prevent 1 cardiovascular event. It is likely that many such patients given this information would choose non drug treatments for hypertension (e.g. diet, exercise, stress management, etc.) rather than drug therapy. They would be even less likely to choose drug treatment when they were told that these estimated benefits are a best case scenario and uncertain based on the best available evidence at this time from this review. Furthermore they must also be told that they have a 9% chance of having an adverse effect that would require them to withdraw from therapy. Withdrawals may not be that high in practice today as lower doses of thiazides and beta-blockers are used today than was used in the MRC trial.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-07-09 21:56:45 -0700" MODIFIED_BY="James M Wright">
<P>The findings of this review are limited by the inability to get individual patient data from all the trials with patients in this subgroup. The number of patients in this review in comparison to the total number of patients in the trials in shown in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. However, even if we had all the data there is a good chance the findings would remain uncertain and inconclusive. This is due to the fact that patients with mild hypertension have a relatively low risk of experiencing an adverse cardiovascular event in keeping with the low number of events that were seen in this review. A 5 year study with 15,000 patients would be required to demonstrate a reduction of 30% in total cardiovascular events and of 45,000 patients to demonstrate a mortality reduction of 10%. Planned subgroup analyses were not conducted due to the paucity of outcomes in the overall data.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-07-09 22:20:16 -0700" MODIFIED_BY="James M Wright" NOTES="&lt;p&gt;&lt;span modified=&quot;2012-06-21 21:21:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;I don't understand this sentence without a comma after &amp;quot;against.&amp;quot;&lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:22:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; Are they biased against justifying why the non-significant benefits are likely to be an overestimate? Please clarify. &lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:21:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; &lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-07-09 22:20:16 -0700" NOTES_MODIFIED_BY="James M Wright">
<P>The trials contributing to this review were funded by granting agencies. Nevertheless the risk of bias assessment suggests that there is a moderate to high risk of bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) making the magnitude of the non-significant relative risk reduction more likely to be an overestimate than an underestimate. In particular the Australian trial (<LINK REF="STD-ANBP" TYPE="STUDY">ANBP</LINK>) had a high risk of ascertainment bias. As a result this trial only contributed to mortality data. The RR estimate of effect on mortality with treatment was unaffected by deselecting this trial. Another limitation is that most of the outcome data comes from the <LINK REF="STD-MRC" TYPE="STUDY">MRC</LINK> trial, which we judged to have a high risk of detection bias and attrition bias. Despite the lack of financial bias in this trial the investigators were more likely to be biased in favour of treatment than against, justifying why the non-significant benefits are likely to be an overestimate. </P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-07-09 22:00:25 -0700" MODIFIED_BY="James M Wright">
<P>It is unlikely that any large unpublished negative trials have been missed. It is over 20 years now since it has been accepted by the medical community that patients with mild hypertension should be treated. Therefore it is highly unlikely that trials have been conducted in this population in the last 20 years. The inability to obtain individual patient data in all relevant trials could have biased the findings. </P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-07-09 22:00:46 -0700" MODIFIED_BY="James M Wright">
<P>As far as we are aware there have been no previous systematic reviews conducted to answer this question. The findings of this review are however in disagreement with hypertension guideline recommendations in the US, Canada and Europe. These guideline groups have recommended treatment of all adults with a blood pressure &gt; 140/90 mmHg. The European Guidelines specify that the recommendation for pharmacologic treatment in "mild uncomplicated hypertension" is based on the outcomes of these 5 trials (<LINK REF="STD-ANBP" TYPE="STUDY">ANBP</LINK>; <LINK REF="STD-MRC" TYPE="STUDY">MRC</LINK>; <LINK REF="STD-FEVER-2005" TYPE="STUDY">FEVER 2005</LINK>; <LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK>; <LINK REF="STD-Oslo" TYPE="STUDY">Oslo</LINK>). They do note that the evidence in favour of this recommendation is scant because older trials of "mild hypertension" treated patients whose blood pressure could be higher than grade 1 hypertension or included secondary prevention patients (<LINK REF="REF-Mancia-2009" TYPE="REFERENCE">Mancia 2009</LINK>). We have excluded the latter 3 RCTs, <LINK REF="STD-FEVER-2005" TYPE="STUDY">FEVER 2005</LINK>, <LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK> and <LINK REF="STD-Oslo" TYPE="STUDY">Oslo</LINK>, because they had &gt;20% of patients with moderate or higher blood pressure and <LINK REF="STD-FEVER-2005" TYPE="STUDY">FEVER 2005</LINK> plus <LINK REF="STD-HDFP" TYPE="STUDY">HDFP</LINK> did not have an appropriate control group. The American Society of Hypertension guidelines refers to the European Guidelines to justify this treatment threshold recommendation. The Canadian guidelines are not explicit as to how they come to their recommendations.<BR/>
</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-07-09 22:06:02 -0700" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-07-09 22:04:06 -0700" MODIFIED_BY="[Empty name]">
<P>Since a large proportion of people treated with antihypertensive therapy are individuals with no previous cardiovascular disease (primary prevention) and mild elevations of blood pressure, the findings of this review have important implications. Most physicians have been treating such patients with false confidence that it was based on RCT evidence. Based on the best available evidence at the present time, this review does not show any significant benefit of antihypertensive drug therapy in reducing mortality, heart attacks, strokes, or overall cardiovascular events. Furthermore drug treatment caused 9% of patients to withdraw due to adverse effects. It is likely that given this evidence many individuals with no cardiovascular disease and mild hypertension would choose non-drug treatments (diet, exercise, stress management, etc.) rather than drug therapy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-07-09 22:06:02 -0700" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2012-06-21 21:35:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;&amp;quot;&lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:34:51 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;In the absence of evidence, it is entirely ethical to conduct a large RCT in primary prevention patients with mild hypertension comparing antihypertensive therapy with placebo.&lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:35:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;&amp;quot;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-06-21 21:35:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;This is a review of the evidence. &lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:36:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;The trials that we reviewed strongly suggest that mor&lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:37:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;tality and CV events are not &lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:41:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;significantly &lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:37:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;reduced with drugs while drugs are associated with &lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:38:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;adverse effects including rare drug caused deaths. &lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:39:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;I think it is arguable whether it is ethical to conduct &lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:40:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;a large RCT with the same drugs as are currently used for HBP&lt;/span&gt;&lt;span modified=&quot;2012-06-22 21:50:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt; unless (1) a diet &lt;/span&gt;&lt;span modified=&quot;2012-06-22 21:51:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;or diet and lifestyle approach preceeds the drug trial and (2) &lt;/span&gt;&lt;span modified=&quot;2012-06-22 21:52:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;the protocol for qualifying as having mild HBP excludes people with pre hypertension and normal variation of BP&lt;/span&gt;&lt;span modified=&quot;2012-06-21 21:40:00 -0700&quot; modified_by=&quot;David K Cundiff&quot; class=&quot;inserted&quot;&gt;.&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-07-09 22:06:02 -0700" NOTES_MODIFIED_BY="[Empty name]">
<P>Evidence based treatment of mild hypertension represents a challenge to the medical and research community. Hypertension, the commonest clinical condition being treated today is being treated with an assumption that it has been established that the benefits of treatment outweigh the harms, when that is not in fact the case for people with no cardiovascular disease (primary prevention) and mild hypertension. In the absence of evidence, it is entirely ethical to conduct a large RCT in primary prevention patients with mild hypertension comparing antihypertensive therapy with placebo. At the present time equipoise exists between the treated and the placebo group. In such an RCT it would be possible to compare the relative and absolute benefits and harms in people at baseline in the higher range 150-159/95-99 mmHg and in the lower range 140-149/90-94 mmHg. By following such an approach we may finally properly define hypertension as "that BP above which the benefits of treatment outweigh the harms".</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-03-22 15:15:23 -0700" MODIFIED_BY="James M Wright">
<P>We would like to thank Doug Salzwedel for helping with the search strategy used in this review. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-07-09 22:07:30 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-07-09 22:06:57 -0700" MODIFIED_BY="[Empty name]">
<P>FG provided the data from the INDANA database for the specific population of interest. JMW, DD, FG were responsible for deciding trials to be included. DD and JMW were responsible for data entry and DD wrote the initial draft. DKC suggested the topic for the review and edited the manuscript. All authors were responsible for interpreting the data and reviewing the final draft.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-09-27 20:55:50 -0700" MODIFIED_BY="[Empty name]"/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-10-17 18:44:00 -0700" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-02-28 16:33:42 -0800" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-02-28 16:33:42 -0800" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ANBP" MODIFIED="2012-02-27 12:40:46 -0800" MODIFIED_BY="James M Wright" NAME="ANBP" YEAR="1980">
<REFERENCE MODIFIED="2012-02-27 12:28:14 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>A report by the Management Committee of the Australian Theraputic Trial in Mild Hypertension</AU>
<TI>Untreated mild hypertension</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>1</VL>
<NO>8265</NO>
<PG>185-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:22:47 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abernethy JD</AU>
<TI>The Australian Therapeutic Trial in Mild Hypertension</TI>
<SO>Hypertension 1984;6(5):774-6</SO>
<YR>1984</YR>
<VL>6</VL>
<NO>5</NO>
<PG>774-776</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:25:43 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abernethy JD</AU>
<TI>The need to treat mild hypertension. Misinterpretation of results from the Australian trial</TI>
<SO>JAMA</SO>
<YR>1986</YR>
<VL>256</VL>
<NO>22</NO>
<PG>3134-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-08 15:02:06 -0800" MODIFIED_BY="James M Wright" NOTES="&lt;p&gt;The Australian Therapeutic Trial in Mild Hypertension. Report by the management committee. The Lancet 1980;1:1261-1267.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-02-08 15:02:06 -0800" NOTES_MODIFIED_BY="James M Wright" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>The Australian Therapeutic Trial in Mild Hypertension. Report by the management committee</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>1</VL>
<PG>1261-1267</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:30:18 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doyle AE</AU>
<TI>Cardiovascular morbidity and mortality in mild hypertension: The Australian Trial</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1985</YR>
<VL>7</VL>
<NO>Suppl 2</NO>
<PG>S10-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:32:25 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doyle AE</AU>
<TI>The Australian Therapeutic Trial in Mild Hypertension</TI>
<SO>Nephron</SO>
<YR>1987</YR>
<VL>47</VL>
<NO>Suppl 1</NO>
<PG>115-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:34:30 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>National Heart Foundation of Australia</AU>
<TI>Treatment of mild hypertension in the elderly</TI>
<SO>Med J Aust</SO>
<YR>1981</YR>
<VL>2</VL>
<PG>398-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:36:40 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parry CA</AU>
<TI>Australian Therapeutic Trial in Mild Hypertension. [Letter]</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>2</VL>
<NO>8191</NO>
<PG>425</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:38:29 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reader R</AU>
<TI>Australian Therapeutic Trial in Mild Hypertension</TI>
<SO>Medical Journal of Australia</SO>
<YR>1984</YR>
<VL>140</VL>
<NO>13</NO>
<PG>752-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:40:44 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Report by Management committee of the ATTMH</AU>
<TI>Initial results of the Australian Therapeutic Trial in mild hypertension (ATTMH)</TI>
<SO>Clinical Science</SO>
<YR>1979</YR>
<VL>57</VL>
<PG>449s-452s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC" MODIFIED="2012-02-28 15:30:28 -0800" MODIFIED_BY="[Empty name]" NAME="MRC" YEAR="1985">
<REFERENCE MODIFIED="2012-02-27 12:44:51 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>2</VL>
<NO>8246</NO>
<PG>539-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:49:59 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension</TI>
<SO>British Heart Journal</SO>
<YR>1988</YR>
<VL>59</VL>
<NO>3</NO>
<PG>364-378</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:52:39 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. Medical Research Council Working Party on Mild Hypertension</TI>
<SO>Brit Med J</SO>
<YR>1986</YR>
<VL>293</VL>
<NO>6553</NO>
<PG>988-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:54:16 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on mild to Moderate Hypertension</TI>
<SO>Brit Med J</SO>
<YR>1977</YR>
<VL>1</VL>
<NO>6074</NO>
<PG>1437-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:55:58 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension</TI>
<SO>Brit Med J</SO>
<YR>1988</YR>
<VL>296</VL>
<NO>6636</NO>
<PG>1565-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-29 19:27:51 -0700" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Medical Research council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985;291(6488):97-104.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-08-29 19:27:51 -0700" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research council Working Party</AU>
<TI>MRC trial of treatment of mild hypertension: principal results</TI>
<SO>Br Med J</SO>
<YR>1985</YR>
<VL>291</VL>
<PG>97-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:57:42 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miall WE. Brennan PJ, Mann AH</AU>
<TI>Medical research Council's Treatment Trial for mild hypertension: an interim report</TI>
<SO>Clinical Science and Molecular Medicine</SO>
<YR>1976</YR>
<VL>51</VL>
<PG>563s-565s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 13:03:44 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peart S. Barnes GR. Briughton PMG. Dollery CT, et al</AU>
<TI>Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1987</YR>
<VL>27</VL>
<NO>4</NO>
<PG>271-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 12:59:30 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peart S</AU>
<TI>Results of the MRC (UK) trial of drug therapy for mild hypertension</TI>
<SO>Clinical and Investigative Medicine</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>6</NO>
<PG>616-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SHEP" MODIFIED="2012-02-28 16:33:42 -0800" MODIFIED_BY="[Empty name]" NAME="SHEP" YEAR="1991">
<REFERENCE MODIFIED="2012-02-27 14:19:09 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Applegate WB. Davis BR. Black HR, et al</AU>
<TI>Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort</TI>
<SO>Journal of American Geriatric Society</SO>
<YR>1991</YR>
<VL>39</VL>
<PG>1057-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:23:21 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bearden D. Allman R. McDonald R, et al</AU>
<TI>Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>1994</YR>
<VL>42</VL>
<PG>1143-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:25:04 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black HR. Unger D. Burlando A, et al</AU>
<TI>Part 6: Baseline physical examination findings.</TI>
<SO>Hypertension 1991;17(3 (Suppl II)):II-77-II-101.</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>Suppl II</NO>
<PG>77-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:26:53 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borhani NO. Applegate WB. Cutler JA, et al</AU>
<TI>Part 1: rationale and design</TI>
<SO>Hypertension</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>Suppl II</NO>
<PG>2-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:32:01 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brittain E. Palensky J. Blood J and Wittes J</AU>
<TI>Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP)</TI>
<SO>Statistics in Medicine</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>681-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:31:38 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curb JD. Lee M. Jensen J, Applegate W</AU>
<TI>Part 4: baseline medical history findings</TI>
<SO>Hypertension</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>Suppl II</NO>
<PG>35-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:31:06 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curb JD. Pressel SL. Cutler JA, et al</AU>
<TI>Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>1886-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:33:32 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis BR. Wittes J. Pressel S, et al</AU>
<TI>Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP)</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1993</YR>
<VL>14</VL>
<PG>350-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:35:12 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franse LV. Pahor M. Di Bari M, et al</AU>
<TI>Serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program</TI>
<SO>Journal of Hypertension</SO>
<YR>2000</YR>
<VL>18</VL>
<PG>1149-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:36:49 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frost PH. Davis BR. Burlando AJ, et al</AU>
<TI>Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program</TI>
<SO>Circulation</SO>
<YR>1996</YR>
<VL>94</VL>
<PG>2381-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:38:54 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall WD. Davis BR. Frost P, et al</AU>
<TI>Part 7: Baseline laboratory characteristics</TI>
<SO>Hypertension</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>Suppl II</NO>
<PG>102-122</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-28 16:33:42 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawkins CM</AU>
<TI>Isolated systolic hypertension, morbidity and mortality: The SHEP experience</TI>
<SO>American Journal of Geriatric Cardiology</SO>
<YR>1993</YR>
<VL>2</VL>
<NO>5</NO>
<PG>25-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:42:54 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kostis JB. Allen R. Berkson DM, et al</AU>
<TI>Correlates of ventricular ectopic activity in isolated systolic hypertension</TI>
<SO>American Heart Journal</SO>
<YR>1994</YR>
<VL>127</VL>
<PG>112-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:44:13 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kostis JB. Davis BR. Cutler J, et al</AU>
<TI>Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>278</VL>
<NO>3</NO>
<PG>212-216</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:45:50 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kostis JB. Lacy CR. Hall D, et al</AU>
<TI>The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension</TI>
<SO>American Journal of Cardiology</SO>
<YR>1994</YR>
<VL>74</VL>
<PG>464-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:47:32 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kostis JB. Prineas R. Curb JD, et al</AU>
<TI>Part 8: Electrocardiographic characteristics.</TI>
<SO>Hypertension</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>Suppl II</NO>
<PG>123-151</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:49:20 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menard J. Day M. Chatellier G, Laragh JH</AU>
<TI>Some lessons from systolic hypertension in the elderly program (SHEP)</TI>
<SO>American Journal of Hypertension</SO>
<YR>1992</YR>
<VL>5</VL>
<PG>325-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:51:13 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newman AB. Tyrrell KS, Kuller LH</AU>
<TI>Mortality over four years in SHEP participants with a low ankle-arm index</TI>
<SO>Journal of American Geriatric Society</SO>
<YR>1997</YR>
<VL>45</VL>
<PG>1472-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:53:12 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry HM. Davis BR. Price TR, et al</AU>
<TI>Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>284</VL>
<NO>4</NO>
<PG>465-471</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:55:17 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrovich H. Byington R. Bailey G, et al</AU>
<TI>Part 2: screening and recruitment</TI>
<SO>Hypertension</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>Suppl II</NO>
<PG>17-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:58:04 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Probstfield JL. Applegate WB. Borhani NO, et al</AU>
<TI>The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension</TI>
<SO>Clinc and Exper Hypertension-Theory and Practice</SO>
<YR>1989</YR>
<VL>A11</VL>
<NO>5 &amp; 6</NO>
<PG>973-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 15:04:13 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>SHEP cooperative Research Group</AU>
<TI>Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1988</YR>
<VL>41</VL>
<NO>12</NO>
<PG>1197-1208</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 15:02:24 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>SHEP cooperative research group</AU>
<TI>Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP</TI>
<SO>ACP Journal Club</SO>
<YR>1991</YR>
<VL>115</VL>
<NO>3</NO>
<PG>65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 14:21:33 -0800" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>SHEP cooperative research group</AU>
<TI>Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>265</VL>
<NO>24</NO>
<PG>3255-64</PG>
<IDENTIFIERS MODIFIED="2009-09-17 10:08:12 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-09-17 10:08:12 -0700" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2046107"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 15:00:21 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Savage PJ. Pressel SL. Curb D, et al</AU>
<TI>Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension</TI>
<SO>Archives of Internal Medicine 1998;158:741-751.</SO>
<YR>1998</YR>
<VL>158</VL>
<PG>741-751</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 15:06:49 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vogt TM. Schron E. Pressel S, et al</AU>
<TI>Part 3: Sociodemographic characteristics</TI>
<SO>Hypertension</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>Suppl II</NO>
<PG>24-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 15:08:31 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wassertheil S. Applegate WB. Berge K, et al</AU>
<TI>Change in depression as a precursor of cardiovascular events</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1996</YR>
<VL>156</VL>
<PG>553-561</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 15:10:18 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wasserthell-Smoller S. FannC. Allman RM, et al</AU>
<TI>Relation of low body mass to death and stroke in the systolic hypertension in the elderly program</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<PG>494-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 15:12:42 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiler PG. Camel GH. Chiappini M, et al</AU>
<TI>Part 9: Behavorial characteristics</TI>
<SO>Hypertension</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>Suppl II</NO>
<PG>152-161</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 15:14:57 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wittes J. Davis B. Berge K, et al</AU>
<TI>Part 10: Analysis</TI>
<SO>Hypertension</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>Suppl II</NO>
<PG>162-167</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-09-14 17:18:55 -0700" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VA_x002d_NHLBI" MODIFIED="2012-02-27 13:13:13 -0800" MODIFIED_BY="[Empty name]" NAME="VA-NHLBI" YEAR="1978">
<REFERENCE MODIFIED="2012-02-27 13:13:13 -0800" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Perry HM Jr., Goldman AI, Lavin MA, Schnaper HW, Fitz AE, et al</AU>
<TI>Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension</TI>
<SO>Ann N Y Acad Sci</SO>
<YR>1978</YR>
<VL>304</VL>
<PG>267-92</PG>
<IDENTIFIERS MODIFIED="2009-08-29 19:27:19 -0700" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-29 19:25:55 -0700" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="360921"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 13:11:49 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry Jr HM, et al</AU>
<TI>Treatment of mild hypertension. Preliminary results of a two year feasibility trial</TI>
<SO>Circ Res</SO>
<YR>1977</YR>
<VL>40</VL>
<NO>suppl</NO>
<PG>1180-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-08 15:03:53 -0800" MODIFIED_BY="[Empty name]"/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-02-27 17:55:17 -0800" MODIFIED_BY="James M Wright">
<STUDY DATA_SOURCE="PUB" ID="STD-COOPE" MODIFIED="2009-10-15 09:49:24 -0700" MODIFIED_BY="James M Wright" NAME="COOPE" YEAR="1986">
<REFERENCE MODIFIED="2009-10-15 09:49:24 -0700" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coope J, Warrender TS</AU>
<TI>Randomised trial of treatment of hypertension in elderly patients in primary care</TI>
<SO>BMJ</SO>
<YR>1986</YR>
<VL>293</VL>
<PG>1145-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FEVER-2005" MODIFIED="2012-02-27 17:14:16 -0800" MODIFIED_BY="James M Wright" NAME="FEVER 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-02-27 17:12:54 -0800" MODIFIED_BY="James M Wright" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A</AU>
<TI>The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients</TI>
<SO>Journal of Hypertension</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>2157-2172</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HDFP" MODIFIED="2012-02-27 17:55:17 -0800" MODIFIED_BY="[Empty name]" NAME="HDFP" YEAR="">
<REFERENCE MODIFIED="2012-02-27 17:49:06 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>HDFP</AU>
<TI>Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5-year findings of the hypertension detection and follow-up program</TI>
<SO>Hypertension</SO>
<YR>1984</YR>
<VL>6</VL>
<NO>Suppl 1</NO>
<PG>198-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 17:51:04 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>HDFP</AU>
<TI>Five-year findings of the hypertension detection and follow-up program III. Reduction in stroke incidence among persons with high blood pressure</TI>
<SO>JAMA</SO>
<YR>1982</YR>
<VL>247</VL>
<PG>633-638</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 17:53:17 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>HDFP</AU>
<TI>The effect of treatment on mortality in &#8220;mild&#8221;hypertension Results of the hypertension detection and follow-up program</TI>
<SO>N Engl J Med</SO>
<YR>1982</YR>
<VL>307</VL>
<PG>976-980</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 17:55:16 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hypertension Detection and Follow-up Program Cooperative Group (HDFP)</AU>
<TI>Five-year findings of the hypertension detection and follow-up program II Mortality by race-sex and age</TI>
<SO>JAMA</SO>
<YR>1979</YR>
<VL>247</VL>
<PG>2572-2576.</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-08 14:41:07 -0800" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hypertension Detection and Follow-up Program Cooperative Group</AU>
<TI>Five-year findings of the Hypertension Detection and Follow-up Program: I.Reduction in mortality of persons with high blood pressure, including mild hypertension</TI>
<SO>JAMA</SO>
<YR>1979</YR>
<VL>242</VL>
<PG>2562-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRC2" MODIFIED="2009-10-15 09:43:02 -0700" MODIFIED_BY="James M Wright" NAME="MRC2" YEAR="1992">
<REFERENCE MODIFIED="2009-09-20 20:20:43 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party</AU>
<TI>Medical Research Council trial of treatment of hypertension in older adults: principal results</TI>
<SO>BMJ</SO>
<YR>1992</YR>
<VL>304</VL>
<PG>405-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MRFIT" MODIFIED="2009-10-15 09:44:11 -0700" MODIFIED_BY="James M Wright" NAME="MRFIT" YEAR="1982">
<REFERENCE MODIFIED="2009-09-27 18:52:08 -0700" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Multiple Risk Factor Intervention Trial Research Group</AU>
<TI>Multiple risk factor intervention trial. Risk factor changes and mortality results</TI>
<SO>JAMA</SO>
<YR>1982 Sep 24</YR>
<VL>248</VL>
<NO>12</NO>
<PG>1465-77</PG>
<IDENTIFIERS MODIFIED="2009-09-27 18:52:08 -0700" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oslo" MODIFIED="2012-02-27 17:41:18 -0800" MODIFIED_BY="James M Wright" NAME="Oslo" YEAR="1980">
<REFERENCE MODIFIED="2012-02-27 17:30:12 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helgeland A, Leren P</AU>
<TI>Oslo study: Treatment of mild hypertension</TI>
<SO>Nephron</SO>
<YR>1987</YR>
<VL>47</VL>
<NO>Suppl 1</NO>
<PG>108-110</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 17:21:58 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helgeland A. Baksaas IA, Leren P</AU>
<TI>Mild hypertension - early drug treatment or follow-up only? the Oslo study</TI>
<SO>Acta Medica Scandinavica. Supplementum</SO>
<YR>1979</YR>
<VL>626</VL>
<PG>34-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 17:24:30 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helgeland A. Hjermann I. Holme I, Liren P</AU>
<TI>Serum triglycerides and serum uric acid in untreated and thiazide-treated patients with mild hypertension</TI>
<SO>The American Journal of Medicine</SO>
<YR>1978</YR>
<VL>64</VL>
<PG>34-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 17:27:54 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helgeland A. Leren P. Foss OP, et al</AU>
<TI>Serum glucose levels during long-term observation of treated and untreated men with mild hypertension</TI>
<SO>The American Journal of Medicine</SO>
<YR>1984</YR>
<VL>76</VL>
<PG>802-805</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-10-15 00:32:50 -0700" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helgeland A</AU>
<TI>Treatment of mild hypertension: a five year controlled drug trial. The Oslo study</TI>
<SO>Am J Med</SO>
<YR>1980 Nov</YR>
<VL>69</VL>
<NO>5</NO>
<PG>725-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="7001898"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 17:32:09 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holme I</AU>
<TI>Coronary risk factors and their possible causal role in the development of coronary heart disease</TI>
<SO>Journal Oslo City Hospital</SO>
<YR>1982</YR>
<VL>32</VL>
<PG>79-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 17:34:01 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holme I. Helgeland A. Hjermann I, et al</AU>
<TI>Correlates of blood pressure change in middle-aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1988</YR>
<VL>127</VL>
<NO>4</NO>
<PG>742-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 17:35:51 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leren P, Helgeland A</AU>
<TI>Coronary heart disease and treatment of hypertension. Some Oslo data</TI>
<SO>The American journal of Medicine</SO>
<YR>1986</YR>
<VL>80</VL>
<NO>Suppl 2A</NO>
<PG>3-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 17:39:37 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leren P, et al</AU>
<TI>Oslo hypertension study</TI>
<SO>Drugs</SO>
<YR>1986</YR>
<VL>31</VL>
<NO>Suppl 1</NO>
<PG>41-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 17:37:40 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leren P. Eide I. Foss OP, et al</AU>
<TI>Blood lipids and antihypertensive drugs</TI>
<SO>Journal of Pharmacology (Paris)</SO>
<YR>1983</YR>
<VL>14</VL>
<NO>Suppl II</NO>
<PG>217-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 17:41:17 -0800" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leren P. Hegeland A. Hjermann I, Holme I</AU>
<TI>The Oslo study: CHD risk factors, socioeconomic influences, and interventions</TI>
<SO>American Heart Journal</SO>
<YR>1983</YR>
<VL>106</VL>
<PG>1200-1206</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-USPHSHC" MODIFIED="2009-10-15 09:48:29 -0700" MODIFIED_BY="James M Wright" NAME="USPHSHC" YEAR="1977">
<REFERENCE MODIFIED="2009-10-15 00:33:37 -0700" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith WM</AU>
<TI>Treatment of mild hypertension: results of a ten-year intervention trial</TI>
<SO>Circ Res</SO>
<YR>1977 May</YR>
<VL>40</VL>
<NO>5 Suppl 1</NO>
<PG>I98-105</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="140029"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-10-17 18:44:00 -0700" MODIFIED_BY="Ciprian D Jauca">
<ADDITIONAL_REFERENCES MODIFIED="2012-10-17 18:44:00 -0700" MODIFIED_BY="Ciprian D Jauca">
<REFERENCE ID="REF-Collins-1990" MODIFIED="2012-02-07 16:12:49 -0800" MODIFIED_BY="Ciprian D Jauca" NAME="Collins 1990" TYPE="JOURNAL_ARTICLE">
<AU>Collins R, Peto R, Macmahon S, Hebert P, et al</AU>
<TI>Blood pressure, stroke, and coronary heart disease- Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>827-838</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gueyffier-1996" MODIFIED="2008-08-12 13:05:54 -0700" MODIFIED_BY="Ciprian D Jauca" NAME="Gueyffier 1996" TYPE="JOURNAL_ARTICLE">
<AU>Gueyffier F, Froment A, Gouton M</AU>
<TI>New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit</TI>
<SO>J Human Hyperten</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mancia-2009" MODIFIED="2012-02-28 16:12:52 -0800" MODIFIED_BY="James M Wright" NAME="Mancia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Mancia G, Laurent S, Agabiti-Rosei E, et al</AU>
<TI>Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document</TI>
<SO>Journal of Hypertension</SO>
<YR>2009</YR>
<VL>27</VL>
<PG>1-38</PG>
<IDENTIFIERS MODIFIED="2012-02-28 16:12:52 -0800" MODIFIED_BY="James M Wright">
<IDENTIFIER MODIFIED="2012-02-28 16:12:52 -0800" MODIFIED_BY="James M Wright" TYPE="DOI" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marchant-2011" MODIFIED="2012-10-17 18:44:00 -0700" MODIFIED_BY="James M Wright" NAME="Marchant 2011" TYPE="JOURNAL_ARTICLE">
<AU>Marchant I, Nony P, Cucherat M, Boissel J-P, Thomas SR, et al</AU>
<TI>The Global Risk Approach Should Be Better Applied in French Hypertensive Patients: A Comparison between Simulation and Observation Studies</TI>
<SO>PLoS ONE</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>3</NO>
<PG>e17508</PG>
<IDENTIFIERS MODIFIED="2012-10-17 18:43:58 -0700" MODIFIED_BY="James M Wright">
<IDENTIFIER MODIFIED="2012-10-17 18:43:58 -0700" MODIFIED_BY="James M Wright" TYPE="DOI" VALUE="e17508. doi:10.1371/journal.pone.0017508"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Psaty-1997" MODIFIED="2012-02-28 16:35:28 -0800" MODIFIED_BY="Ciprian D Jauca" NAME="Psaty 1997" TYPE="JOURNAL_ARTICLE">
<AU>Psaty BM, Smith NL, Siscovick DS, Koepsell TD, et al</AU>
<TI>Health outcomes associated with antihypertensive therapies used as first- line agents. A systematic review and meta-analysis</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>277</VL>
<PG>739-745</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Psaty-2003" MODIFIED="2008-08-12 13:03:37 -0700" MODIFIED_BY="Ciprian D Jauca" NAME="Psaty 2003" TYPE="JOURNAL_ARTICLE">
<AU>Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS</AU>
<TI>Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>19</NO>
<PG>2534-2544</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quan-2000" MODIFIED="2008-08-12 13:02:23 -0700" MODIFIED_BY="Ciprian D Jauca" NAME="Quan 2000" TYPE="COCHRANE_REVIEW">
<AU>Quan A, Kerlikowske K, Gueyffier F, Boissel JP, for the INDANA Investigators</AU>
<TI>Pharmacotherapy for hypertension in women of different races</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-08-12 13:01:32 -0700" MODIFIED_BY="Ciprian D Jauca">
<IDENTIFIER MODIFIED="2008-08-12 13:01:32 -0700" MODIFIED_BY="Ciprian D Jauca" TYPE="DOI" VALUE="10.1002/14651858.CD002146"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Therapeutics-Initiative-2007" MODIFIED="2012-07-09 22:27:43 -0700" MODIFIED_BY="James M Wright" NAME="Therapeutics Initiative 2007" TYPE="JOURNAL_ARTICLE">
<AU>Therapeutics Intitiative</AU>
<TI>Mild Hypertension- An approach to using evidence in the decision making process</TI>
<SO>Therapeutics Letter</SO>
<YR>Jan-Feb 2007</YR>
<VL>62</VL>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wright-1999" MODIFIED="2008-08-12 13:04:09 -0700" MODIFIED_BY="Ciprian D Jauca" NAME="Wright 1999" TYPE="JOURNAL_ARTICLE">
<AU>Wright JM. Cheng-Han Lee and Chambers KC</AU>
<TI>Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?</TI>
<SO>CMAJ</SO>
<YR>1999</YR>
<VL>161</VL>
<PG>25-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wright-2009" MODIFIED="2012-02-28 16:37:07 -0800" MODIFIED_BY="James M Wright" NAME="Wright 2009" TYPE="COCHRANE_REVIEW">
<AU>Wright JM, Musini VM</AU>
<TI>First-line drugs for hypertension</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-02-28 16:37:07 -0800" MODIFIED_BY="James M Wright">
<IDENTIFIER MODIFIED="2012-02-28 16:37:07 -0800" MODIFIED_BY="James M Wright" TYPE="DOI" VALUE="10.1002/14651858.CD001841"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-07-09 22:11:25 -0700" MODIFIED_BY="James M Wright">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-07-09 22:11:25 -0700" MODIFIED_BY="James M Wright" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-02-09 20:28:01 -0800" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ANBP">
<CHAR_METHODS MODIFIED="2012-02-08 14:04:04 -0800" MODIFIED_BY="[Empty name]">
<P>Randomised single-blind, comparing treatment with placebo. Trial conducted in Australia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-21 19:01:28 -0700" MODIFIED_BY="[Empty name]">
<P>Ambulatory young patients, with mean age 50 years, range (30-59 years). Australian (White) or European born, the former predominating. Male (63%). Baseline mean SBP/DBP was 157.4/100.4 mmHg. The inclusion criteria was SBP &lt; 200 mmHg and DBP 90-110 mmHg. Patients were followed for 4 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-09 20:28:01 -0800" MODIFIED_BY="[Empty name]">
<P>Chlorothiazide 500mg once or twice daily, methyldopa, propranolol, or pindolol added as 2nd-order treatment, and hydralazine or clonidine added as 3rd-order treatment. Control: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-21 19:12:14 -0700" MODIFIED_BY="[Empty name]">
<P>Mortality, CHD, stroke, other CV events, systolic BP and diastolic BP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-08 14:05:05 -0800" MODIFIED_BY="James M Wright">
<P>Attrition bias for ANBPS trial : All components from the composite outcome were terminating events, without complementary mortality survey. All analyses regarding these separated components are subject to a censoring bias.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-09 20:29:21 -0800" MODIFIED_BY="James M Wright" STUDY_ID="STD-MRC">
<CHAR_METHODS MODIFIED="2009-09-21 18:27:23 -0700" MODIFIED_BY="[Empty name]">
<P>Randomised single-blind comparing 2 treatments and placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-23 04:56:59 -0700" MODIFIED_BY="[Empty name]">
<P>Ambulatory patients, with mean age 52 years, range (35-64 years). Ethnicity not reported. Male (52%). Baseline mean SBP/DBP was 161.4/98.2 mmHg and pulse pressure was 63 mmHg. The inclusion criteria was SBP &lt; 200 mmHg and DBP 90-109 mmHg. Patients were followed for 5 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-09 20:29:21 -0800" MODIFIED_BY="James M Wright">
<P>Bendrofluazide 10 mg daily (71% mono), Propranolol 80-240 mg daily (78% mono), methyldopa added if required. Control: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-21 18:27:16 -0700" MODIFIED_BY="[Empty name]">
<P>Mortality, stroke, CHD, systolic BP and diastolic BP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-21 18:27:56 -0700" MODIFIED_BY="[Empty name]">
<P>No CHF data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-09 20:30:07 -0800" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SHEP">
<CHAR_METHODS MODIFIED="2009-09-21 19:16:01 -0700" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo controlled. Trial conducted in USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-09 20:30:07 -0800" MODIFIED_BY="[Empty name]">
<P>Ambulatory patients, with mean age 72 years, range (&gt; 60 years). 13.9% of patients were African-Americans. Male (43%). Baseline mean SBP/DBP was 170/77 mmHg and pulse pressure was 93 mmHg. The inclusion criteria was SBP 160-219 mmHg and DBP &lt;90 mmHg. Patients were followed for 4.5 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-21 19:20:55 -0700" MODIFIED_BY="[Empty name]">
<P>Chlorthalidone 12.5-25 mg (69%), Step 2. atenolol 25-50 mg (23%) or reserpine 0.05-0.1 mg. Identical placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-21 19:16:40 -0700" MODIFIED_BY="[Empty name]">
<P>Mortality, stroke, CHD, CHF, systolic BP and diastolic BP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-21 19:16:52 -0700" MODIFIED_BY="[Empty name]">
<P>Total CVS verified remains same</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-09 20:31:04 -0800" MODIFIED_BY="James M Wright" STUDY_ID="STD-VA_x002d_NHLBI">
<CHAR_METHODS MODIFIED="2009-09-21 19:19:39 -0700" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo controlled. Trial conducted in USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-14 03:52:24 -0700" MODIFIED_BY="James M Wright">
<P>Ambulatory patients, with mean age 37.5 years, range (21-50 years). 25% patients were African-Americans. Male (100%). Baseline mean DBP was 93.3 mmHg. The inclusion criteria was DBP 85-105 mmHg. Patients were followed for 2 years. Target &lt; 85 mmHg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-09 20:31:04 -0800" MODIFIED_BY="[Empty name]">
<P>CHTD 50 mg, 100 mg, (53% CHTD alone). Reserpine 0.25 mg. Control: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-21 19:21:55 -0700" MODIFIED_BY="[Empty name]">
<P>Mortality, stroke, CHD, CHF, and diastolic BP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-02-08 14:42:13 -0800" MODIFIED_BY="James M Wright" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-09-20 20:11:00 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-COOPE">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-20 20:11:00 -0700" MODIFIED_BY="[Empty name]">
<P>Only 2 subjects met criteria defined in this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-08 14:42:13 -0800" MODIFIED_BY="James M Wright" STUDY_ID="STD-FEVER-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-08 14:42:13 -0800" MODIFIED_BY="James M Wright">
<P>Not a placebo or no treatment controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-15 09:41:12 -0700" MODIFIED_BY="James M Wright" STUDY_ID="STD-HDFP">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-15 09:41:12 -0700" MODIFIED_BY="James M Wright">
<P>No untreated control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-20 20:11:24 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MRC2">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-20 20:11:24 -0700" MODIFIED_BY="[Empty name]">
<P>Only 2 subjects met criteria defined in this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-27 18:52:48 -0700" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MRFIT">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-27 18:52:48 -0700" MODIFIED_BY="[Empty name]">
<P>No untreated / placebo control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-15 09:46:14 -0700" MODIFIED_BY="James M Wright" STUDY_ID="STD-Oslo">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-15 09:46:14 -0700" MODIFIED_BY="James M Wright">
<P>Approximately half of the subjects had moderately elevated BP and data was not available for the subjects with mild elevation of BP separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-15 09:46:43 -0700" MODIFIED_BY="James M Wright" STUDY_ID="STD-USPHSHC">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-15 09:46:43 -0700" MODIFIED_BY="James M Wright">
<P>Approximately half of the subjects had moderately elevated BP and data was not available for the subjects with mild elevation of BP separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-07-09 22:11:25 -0700" MODIFIED_BY="James M Wright">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-07-09 22:11:25 -0700" MODIFIED_BY="James M Wright" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-09 22:07:49 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ANBP">
<DESCRIPTION>
<P>"patients randomly allocated, with stratification by age and sex" Not enough detail to know how this was done. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-09 22:11:25 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MRC">
<DESCRIPTION>
<P>"Randomisation was in stratified blocks of eight within each sex, 10 year age group, and clinic." Sufficient detail provided to consider low risk. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-23 05:01:28 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHEP">
<DESCRIPTION>
<P>"Screenees were randomly allocated by the coordinating center to one of two treatment groups. Randomization was stratified by clinical center and by antihypertensive medication status at initial contact."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-27 18:41:45 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VA_x002d_NHLBI">
<DESCRIPTION>
<P>Use of randomization number and subjects were "randomized in double-blind fashion into active drug therapy and placebo groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-10-23 04:58:48 -0700" MODIFIED_BY="James M Wright" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 19:12:49 -0700" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-ANBP">
<DESCRIPTION>
<P>Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-23 04:58:48 -0700" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MRC">
<DESCRIPTION>
<P>Not described. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 19:18:58 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHEP">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 19:22:12 -0700" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VA_x002d_NHLBI">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-02-08 14:13:31 -0800" MODIFIED_BY="James M Wright" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-08 14:06:45 -0800" MODIFIED_BY="James M Wright" RESULT="NO" STUDY_ID="STD-ANBP">
<DESCRIPTION>
<P>Trial was single blind so investigators physicians caring for the patient were not blinded as to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-10-23 05:00:00 -0700" MODIFIED_BY="James M Wright" RESULT="NO" STUDY_ID="STD-MRC">
<DESCRIPTION>
<P>Trial was single blind. Investigators knew what treatment the patients were receiving.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-08 14:11:53 -0800" MODIFIED_BY="James M Wright" RESULT="YES" STUDY_ID="STD-SHEP">
<DESCRIPTION>
<P>Blinding of patients and investigators was achieved.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-08 14:13:31 -0800" MODIFIED_BY="James M Wright" RESULT="UNKNOWN" STUDY_ID="STD-VA_x002d_NHLBI">
<DESCRIPTION>
<P>Blinding of investigators and patients was achieved.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-02-08 14:13:47 -0800" MODIFIED_BY="James M Wright" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-08 14:07:25 -0800" MODIFIED_BY="James M Wright" RESULT="NO" STUDY_ID="STD-ANBP">
<DESCRIPTION>
<P>All components from the composite outcome were terminating events, without complementary mortality survey. All analyses regarding these separated components are subject to a censoring bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-08 14:10:39 -0800" MODIFIED_BY="James M Wright" RESULT="NO" STUDY_ID="STD-MRC">
<DESCRIPTION>
<P>Myocardial infarction and stroke were reasons for terminating the study follow-up, except for death flagging. This induces a censoring attrition bias, limited to the occurrence non-fatal events myocardial infarction or stroke. In the original paper : TERMINATION OF PARTICIPATION IN TRIAL Events terminating a patient's participation were: stroke, whether fatal or non-fatal; coronary events, including sudden death thought to be due to a coronary cause, death known to be due to myocardial infarction, and non-fatal myocardial infarction; other cardiovascular events, including deaths due to hypertension (ICD 400-404) and to rupture or dissection of an aortic aneurysm; and death from any other cause. Clinic staff reported these events to the coordinating centre. The records of all patients who suffered non-fatal terminating events and of any others who lapsed from the trial, whatever the reason, were "flagged" at the Southport NHS central register to ensure notification of death.)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-08 14:12:39 -0800" MODIFIED_BY="James M Wright" RESULT="YES" STUDY_ID="STD-SHEP">
<DESCRIPTION>
<P>Patients with non-fatal outcomes were not censored. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-08 14:13:47 -0800" MODIFIED_BY="James M Wright" RESULT="UNKNOWN" STUDY_ID="STD-VA_x002d_NHLBI">
<DESCRIPTION>
<P>Not specified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-02-08 14:13:54 -0800" MODIFIED_BY="James M Wright" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-08 14:08:05 -0800" MODIFIED_BY="James M Wright" RESULT="UNKNOWN" STUDY_ID="STD-ANBP">
<DESCRIPTION>
<P>Not specified in report. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-08 14:11:14 -0800" MODIFIED_BY="James M Wright" RESULT="UNKNOWN" STUDY_ID="STD-MRC">
<DESCRIPTION>
<P>Not described in report</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-08 14:12:54 -0800" MODIFIED_BY="James M Wright" RESULT="UNKNOWN" STUDY_ID="STD-SHEP">
<DESCRIPTION>
<P>Not specified in report. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-08 14:13:54 -0800" MODIFIED_BY="James M Wright" RESULT="UNKNOWN" STUDY_ID="STD-VA_x002d_NHLBI">
<DESCRIPTION>
<P>Not specified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-07-09 22:13:31 -0700" MODIFIED_BY="James M Wright">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-07-09 22:13:31 -0700" MODIFIED_BY="James M Wright" NO="1">
<TITLE MODIFIED="2012-02-28 14:47:58 -0800" MODIFIED_BY="James M Wright">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TD COLSPAN="7">
<P>
<B>Antihypertensive drug therapy compared with placebo for mild hypertension</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: Adults </B>with mild hypertension and no cardiovascular disease</P>
<P>
<B>Settings: ambulatory</B>
</P>
<P>
<B>Intervention: Stepped care antihypertensive drug therapy </B>
</P>
<P>
<B>Comparison: Placebo </B>
</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Placebo</P>
</TH>
<TH VALIGN="TOP">
<P>Antihypertensive drugs</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mortality</B>
</P>
<P>
<B>4 to 5 years</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.85</B> (0.63 to 1.15)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>8912<BR/>(4)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>More RCTs needed as a significant benefit may have been missed. </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>13 per 1000</B>
<BR/>(9 to 17)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>30 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>26 per 1000</B>
<BR/>(18 to 34)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Total CV events</B>
</P>
<P>5 years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.97</B> (0.72 to 1.32)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>7080<BR/>(3)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
<P/>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>More RCTs needed as wide confidence intervals are consistent with a significant benefit or a significant harm. </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>15 per 1000</B>
<BR/>(11 to 20)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>30 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>29 per 1000</B>
<BR/>(22 to 40)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Withdrawals due to adverse effects</B>
</P>
<P>5 years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Low risk population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 4.80</B> (4.14 to 5.57)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>17,354<BR/>(1)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
<P/>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Withdrawals due to adverse effects are increased. It was downgraded to moderate as it was not limited to a primary prevention population with mild hypertension.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>72 per 1000</B>
<BR/>(62 to 84)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>High risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>30 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>144 per 1000</B>
<BR/>(124 to 168)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>The median control group risk was derived from the event rate in the control group i.e. 20 per 1000 mortality, 24 per 1000 total CV events and 23 per 1000 withdrawals due to adverse effects. </P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-07-09 22:15:36 -0700" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-07-09 22:15:36 -0700" MODIFIED_BY="James M Wright" NO="1">
<TITLE MODIFIED="2012-07-09 22:15:36 -0700" MODIFIED_BY="James M Wright">Patient numbers in this review versus total numbers in the trials</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TD>
<P>Trials</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>This review </P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>Total</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>Placebo</P>
</TD>
<TD ALIGN="CENTER">
<P>Treatment</P>
</TD>
<TD ALIGN="CENTER">
<P>Placebo </P>
</TD>
</TR>
<TR>
<TD>
<P>MRC</P>
</TD>
<TD ALIGN="CENTER">
<P>3012</P>
</TD>
<TD ALIGN="CENTER">
<P>3049</P>
</TD>
<TD ALIGN="CENTER">
<P>8700</P>
</TD>
<TD ALIGN="CENTER">
<P>8654</P>
</TD>
</TR>
<TR>
<TD>
<P>ANBP</P>
</TD>
<TD ALIGN="CENTER">
<P>958</P>
</TD>
<TD ALIGN="CENTER">
<P>874</P>
</TD>
<TD ALIGN="CENTER">
<P>1721</P>
</TD>
<TD ALIGN="CENTER">
<P>1706</P>
</TD>
</TR>
<TR>
<TD>
<P>SHEP</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>2365</P>
</TD>
<TD ALIGN="CENTER">
<P>2371</P>
</TD>
</TR>
<TR>
<TD>
<P>VA-NHLBI</P>
</TD>
<TD ALIGN="CENTER">
<P>508</P>
</TD>
<TD ALIGN="CENTER">
<P>504</P>
</TD>
<TD ALIGN="CENTER">
<P>508</P>
</TD>
<TD ALIGN="CENTER">
<P>504</P>
</TD>
</TR>
<TR>
<TD>
<P>Total </P>
</TD>
<TD ALIGN="CENTER">
<P>4481</P>
</TD>
<TD ALIGN="CENTER">
<P>4431</P>
</TD>
<TD ALIGN="CENTER">
<P>13294</P>
</TD>
<TD ALIGN="CENTER">
<P>13235</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-07-03 12:35:24 -0700" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-07-03 12:35:24 -0700" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Treatment versus No Treatment</NAME>
<DICH_OUTCOME CHI2="2.5587546386853584" CI_END="1.1487517194546835" CI_START="0.6294488758921472" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8503413893783612" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="90" I2="21.83697609132372" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.06022617444781037" LOG_CI_START="-0.20103953770794317" LOG_EFFECT_SIZE="-0.07040668163006639" METHOD="MH" MODIFIED="2012-02-08 15:00:44 -0800" MODIFIED_BY="James M Wright" NO="1" P_CHI2="0.2782105999551523" P_Q="1.0" P_Z="0.2908064584575194" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4481" TOTAL_2="4431" WEIGHT="100.00000000000001" Z="1.0563541547590636">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>No Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.441905204085036" CI_START="0.5828733309067899" EFFECT_SIZE="1.1930303516942349" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.38772880041890784" LOG_CI_START="-0.23442581516431624" LOG_EFFECT_SIZE="0.07665149262729581" MODIFIED="2012-02-08 15:00:44 -0800" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.36545670090860194" STUDY_ID="STD-ANBP" TOTAL_1="958" TOTAL_2="874" VAR="0.13355860023899935" WEIGHT="15.002065253430553"/>
<DICH_DATA CI_END="1.0680899060630658" CI_START="0.5443417430762829" EFFECT_SIZE="0.7624997844121351" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="77" LOG_CI_END="0.02860781080462019" LOG_CI_START="-0.2641283603502738" LOG_EFFECT_SIZE="-0.11776027477282684" MODIFIED="2009-08-30 13:46:04 -0700" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.1719546760038022" STUDY_ID="STD-MRC" TOTAL_1="3012" TOTAL_2="3049" VAR="0.029568410599572593" WEIGHT="84.44405244296473"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-14 17:25:03 -0700" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.0" STUDY_ID="STD-SHEP" TOTAL_1="3" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="103.07068769140896" CI_START="0.23875475328084425" EFFECT_SIZE="4.960707269155206" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0131351736843834" LOG_CI_START="-0.6220479734485406" LOG_EFFECT_SIZE="0.6955436001179214" MODIFIED="2009-10-15 00:37:05 -0700" MODIFIED_BY="James M Wright" ORDER="732" O_E="0.0" SE="1.5479196249928346" STUDY_ID="STD-VA_x002d_NHLBI" TOTAL_1="508" TOTAL_2="504" VAR="2.396055165437958" WEIGHT="0.553882303604719"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0794818637893826" CI_START="0.23731739479669273" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5061420982735724" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.03321535021600321" LOG_CI_START="-0.6246704278705302" LOG_EFFECT_SIZE="-0.2957275388272635" METHOD="MH" MODIFIED="2009-10-15 01:38:41 -0700" MODIFIED_BY="James M Wright" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.07806007568727241" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3523" TOTAL_2="3557" WEIGHT="100.0" Z="1.7620545834686476">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>No Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0794818637893828" CI_START="0.23731739479669267" EFFECT_SIZE="0.5061420982735724" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="20" LOG_CI_END="0.0332153502160033" LOG_CI_START="-0.6246704278705303" LOG_EFFECT_SIZE="-0.2957275388272635" MODIFIED="2009-08-30 13:43:23 -0700" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.3864453626351529" STUDY_ID="STD-MRC" TOTAL_1="3012" TOTAL_2="3049" VAR="0.1493400183022148" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-14 17:24:16 -0700" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.0" STUDY_ID="STD-SHEP" TOTAL_1="3" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-10-15 00:41:36 -0700" MODIFIED_BY="James M Wright" ORDER="734" O_E="0.0" SE="0.0" STUDY_ID="STD-VA_x002d_NHLBI" TOTAL_1="508" TOTAL_2="504" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.41816619777854613" CI_END="1.5662599446689502" CI_START="0.8021074868758369" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1208518314267497" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.1948638414809859" LOG_CI_START="-0.09576742993384275" LOG_EFFECT_SIZE="0.04954820577357156" METHOD="MH" MODIFIED="2009-10-15 01:38:41 -0700" MODIFIED_BY="James M Wright" NO="3" P_CHI2="0.5178535140872207" P_Q="1.0" P_Z="0.5039497617771057" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3523" TOTAL_2="3557" WEIGHT="100.0" Z="0.6682880224280293">
<NAME>Coronary Heart Disease</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>No Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.536186483344562" CI_START="0.7605680013283006" EFFECT_SIZE="1.0809136336011884" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="59" LOG_CI_END="0.1864439395050983" LOG_CI_START="-0.11886195020878784" LOG_EFFECT_SIZE="0.033790994648155215" MODIFIED="2009-08-30 13:38:58 -0700" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.17933819090646455" STUDY_ID="STD-MRC" TOTAL_1="3012" TOTAL_2="3049" VAR="0.03216218671760353" WEIGHT="92.1146794273556"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-24 16:17:51 -0700" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.0" STUDY_ID="STD-SHEP" TOTAL_1="3" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.819327849266496" CI_START="0.5228620750653103" EFFECT_SIZE="1.5874015748031496" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6829864714940296" LOG_CI_START="-0.281612857858968" LOG_EFFECT_SIZE="0.20068680681753082" MODIFIED="2009-10-15 00:39:30 -0700" MODIFIED_BY="James M Wright" ORDER="733" O_E="0.0" SE="0.5666104209056388" STUDY_ID="STD-VA_x002d_NHLBI" TOTAL_1="508" TOTAL_2="504" VAR="0.32104736907886516" WEIGHT="7.885320572644405"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8068210445273466" CI_END="1.3176342057695962" CI_START="0.7208427758455156" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9745804730426098" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.11979486058804927" LOG_CI_START="-0.1421594496060564" LOG_EFFECT_SIZE="-0.011182294509003567" METHOD="MH" MODIFIED="2009-10-15 00:43:02 -0700" MODIFIED_BY="James M Wright" NO="4" P_CHI2="0.3690618372170483" P_Q="1.0" P_Z="0.8671074740819372" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3523" TOTAL_2="3557" WEIGHT="100.00000000000001" Z="0.1673337192728518">
<NAME>Total CV events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>No Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.280701507248045" CI_START="0.6832010587314972" EFFECT_SIZE="0.9354018525055895" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="79" LOG_CI_END="0.10744792064184425" LOG_CI_START="-0.16545146930837987" LOG_EFFECT_SIZE="-0.02900177433326779" MODIFIED="2009-09-24 16:16:44 -0700" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.1603024525305285" STUDY_ID="STD-MRC" TOTAL_1="3012" TOTAL_2="3049" VAR="0.025696876287302342" WEIGHT="93.99100656071448"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-24 16:18:28 -0700" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.0" STUDY_ID="STD-SHEP" TOTAL_1="3" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.819327849266496" CI_START="0.5228620750653103" EFFECT_SIZE="1.5874015748031496" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6829864714940296" LOG_CI_START="-0.281612857858968" LOG_EFFECT_SIZE="0.20068680681753082" MODIFIED="2009-10-15 00:43:02 -0700" MODIFIED_BY="James M Wright" ORDER="735" O_E="0.0" SE="0.5666104209056388" STUDY_ID="STD-VA_x002d_NHLBI" TOTAL_1="508" TOTAL_2="504" VAR="0.32104736907886516" WEIGHT="6.008993439285527"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.569064284006882" CI_START="4.1406938474720985" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.802061038446294" ESTIMABLE="YES" EVENTS_1="980" EVENTS_2="203" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.7457822310031246" LOG_CI_START="0.6170731210436133" LOG_EFFECT_SIZE="0.681427676023369" METHOD="MH" MODIFIED="2011-10-23 05:36:19 -0700" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8700" TOTAL_2="8654" WEIGHT="100.0" Z="20.75336708481273">
<NAME>Withdrawals due to adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>No Treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.569064284006882" CI_START="4.1406938474720985" EFFECT_SIZE="4.802061038446294" ESTIMABLE="YES" EVENTS_1="980" EVENTS_2="203" LOG_CI_END="0.7457822310031246" LOG_CI_START="0.6170731210436133" LOG_EFFECT_SIZE="0.681427676023369" MODIFIED="2011-10-23 05:36:19 -0700" MODIFIED_BY="James M Wright" ORDER="15" O_E="0.0" SE="0.07560436831058653" STUDY_ID="STD-MRC" TOTAL_1="8700" TOTAL_2="8654" VAR="0.0057160205076428215" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-07-09 22:11:27 -0700" MODIFIED_BY="James M Wright">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-02-28 15:31:48 -0800" MODIFIED_BY="James M Wright" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAALYCAYAAABWqXRtAABhn0lEQVR42u29CdhV4/7/f8iQkAxF
phShMhQdNJGrQjqUZCh0OSopQx0ZThI68jVlSJO+ZDqGr6EyfEMhJYkcUoaoTjo5KU4Zkoi4/7/3
/fuv/Vt7PWu4997reZ79PPv1uq591bP3Wvdaa+/P/Xmve1j3+w/Gxx/+8AdeJfQqNvhNiD+omvzB
X4mhxH78IvrNiT/iD6q4kPCDUplJKMBvDwX8jvyQBMEfSvLYQPwBQgIICRB/gJAAQkL8EX/EAEIC
VGSSCBADCEkSv/zyi1m7dm3sNqtXrzaffvqp3TaJX3/91W77/fffx2731VdfmTVr1pTUD3Lttdea
GTNmICRV8HepjN8uXx588EEzceJEhATKX0hGjRplOnToYGrVqmVGjhwZus3ixYtN06ZNza677mrq
1KljttpqK/O///u/kWXef//9Zuuttzb16tUz2223nTnuuOPMwoULs7ZRgO+///6mfv36pmbNmqZN
mzZlKujnn39eZl76FltsUeV/kL333tvceuutJS8kp556qtl5553Nf/7zn6z333//fbvPxo0bi+53
CW5z9tln2+uIw2Wb8qCyjouQlKCQ9OjRw9x+++1m9913DxWSdevWWQEZMWKE+f33321L44033jBL
ly6NLPO9994zb7/9tt1eSaJly5bmggsuyNrmgQcesNt4LZ1jjz3WiorKDwrJI488Yp5++mn7euaZ
ZxCSaiQk+qxfv35VVkgee+wx89BDD2X+fuGFF8zo0aOz9glug5BAtRMSj4YNG4YKyV133WX222+/
gk7glltusSIRx8MPP2yDTd1hQSFJ6h5DSKqukGyzzTZmyy23NO+++26VFJIgF154oWnfvn1RxBlC
AkUjJEcffbQZMGBAQSfQpUsXc9ZZZ8VuM3XqVBtsX3zxRUFCcuWVV5pLL73UPPHEE+bggw+2Qih+
++03c80115g999zT7LHHHubGG2/M2k+f33HHHbYLT91xjRo1yrR+9NnNN99sDjzwQFO7dm3Trl27
rMSXdNyrrrrKCqkEecyYMWWS0YoVK0zv3r3NbrvtZs9twoQJJSMkao3UrVvXxplasGFC4vL9B5ky
ZYrp3r27/T5btGhhxo8fX+b3TvpdXLbxfndx991326667bff3hxyyCHmsssuK7NNrvGk1r+6fffZ
Zx97Q5bLNSIkUDRConEOJV0119X91LlzZ/PSSy8llqcB9GeffdZWplatWplly5Yl3j01a9Ys6z1P
SFSh7r33XvPdd9853YVp7EWJSV1iS5Ysse9rkPSggw4yr732mnnqqafMjjvuaM/P47rrrjM1atSw
Y0baR+M1H330kf3s+uuvtwlCXYDz58+3x9h2223N8uXLE4+rfdU1qEqu8vr06WPHefzJaODAgfZ7
VXfh3LlzzYIFC0pGSJSovdaoujvDhMTl+w+ipD5u3DjbwlW3rLZfv3595nOX38VlG3+y1vmccsop
pnnz5mb27NmZ+AkmdNd4ktCoTug6brjhBvudqE64XiNCAkUhJJs2bbIVZ9999zXnn3++HWDv1auX
fe/111+PLe/qq6+2A/jqtrjzzjtjZ3ppcF6D+F7F8/jmm2+sAKhFo8SvSq1EmyQkanVoNpjHzz//
bO8SVfE8Tj755EwrSZ+rFdKxY8cy5ek70L6DBg3KvLd582Z7PhKAuOPqmnVdV1xxRZnuEf/dpe44
9b3qTrXUurYkJELdQbpp0c2CX0hcv/84lFxV3rRp05x/F9ffLpisw7q2/NvkEk+77LJLpqtX56MJ
LPfdd5/TNSIkUDRCogCXEBxzzDFZ7zdu3Nh07do1sUwF/5tvvmmaNGliWzNhqCtId2dz5syJLUuD
8OoyUpdTrv3Cn3zyiQ3kI444whx//PH2pYTgXZf3ubq2gmjGmj5TK8bPCSeckHVNYcdVK0z7Pvnk
k2WSkf+uVl1ouptU94RaTKUoJPoNNF6iBOsXEtfvPwy1CnSnruSuMiZPnuz8u7j+drkKSSHxJGFR
C8TlGhESKKquLd1lDxkyJOu9/v3726TnirosdA7//Oc/s95XF9kOO+xgK4MLY8eOteX8+9//zklI
PvzwQ7ufuhSUtL3XK6+8kvV52Jz7Dz74wH724osvZr3frVs3240Vd9xFixbZfV999dXYZCQ0Pfqk
k06yrb2oadjVWUiExrA0tdzr6pKQuH7/fjTWohaebjrUetDv7E+yLr+L62+Xq5AUEk9+IUm6RoQE
ikpIFOBHHnlk1nvqz3dpkXio0ugc/IKhvl418aOa6mGoxaByNF04FyFR15Xudi+55JLQfX766Sf7
ufq3g2zYsMG2ytTF5kcDxOedd17scVXZNYDuTzw6l+B7foYOHWoTRtrdXFVBSCQcikPdvHhC4vr9
+1EXqfafOXNmpmXsT7Iuv4vrbxf83XWT1bp168iYLCSe/EKSdI0ICVSokKiy/vjjj6ZBgwb2jl3/
949naNBZgT9v3jz7twYH9QChZox43HTTTbZZrn29O3wv2WvQXQ88qhL4Z1+deeaZtjWiWSkq23t5
ZYgffvgh87cGIg877LDEllBU5dGYjbrQHn/8cSsc6ov3z5RRq0vXpQF4denpGnT3KPQMjLrz1P2m
RKAZN/pO33rrrcTjahxG++rOVt+dWh0aO/L3s0+aNMnO3JJ4DB482LRt27YkWyT+mw7/YLvL9+9H
Nylq2Wn226pVq+xvr+016yqX38Vlm+Dvrt9S423+m53gNvnGk19IXK4RIYEKE5K99tqrzNPjmsHk
R4PlSrIKfs1sCn6uqavaT4lf/OUvf7F/a3t1VWjqYvCpdY2bhDmqeclb6OEu7a/ZVqo0GtP47LPP
8hIS3U1efvnldixCLSFVdm3rb5WoW0LH00uDn950SomOhE+CqkSiCq3lJ1yOqy4STR3VteluVtOc
g90jGmzXMTW4q4c3k8aLqrOQiNNPPz1LSFy+/yCaLajfWnE7bNgwc9FFF9nf3OvOdPldXLYJ/u56
gFezFNXC1THDtsk3noJjJEnXiJBAhXdtJaGWwT/+8Y/QKbiq8MGHFlWhdMfvujZXGBpg16CnWir+
50sKQWXqbs7/BH2wm2vlypWZZxqC30HUZ0no/OO6q3Tc8lxzrDqstZXr969Y1ffqoTv3XH8X122C
fPnll1nHTuN68r1GhASKRkji0PTd2267jW+6uIOAJALEABSvkCTdeQFCAsQfICRARSaJADGAkAAV
mSQCxABUgpBUppGPBtr1kNoZZ5yRNd24EKqSMRFCUvmUarwQA+AsJC7TAytqyfPguehZDj33oYcQ
9SCjvEvSmM5YGUu4IyRVN4mUarwQA+AsJC6GO+VRkVzMf7Q4o+bZ+z0p0jAIQkhIIsQLMQApCkll
VSQX8x+te6UHB0kMCAlCQvxBEQtJmOGOi9lPnEFUkiGPi/mPWh0qXy0SbaMxkqjzTTKrSroeKnLl
HRsTMuIPqoGQhBnuJBn5JBlEJRnyuJj/6Eli+UAoSWgbecCHnW/SubhcDxW58o6NCRnxB9VMSFyM
fJIMorwykwx5kpba9rq2tKhj1DZJ5+JqTERFrlwhwYSM+INqJCQuRj5JBlFhgiCCi82lISRJ5+Jq
TERFrlwhwYSM+INqJCQuRj5JBlEVKSRJ55KLqRQVuXiEBBMy4g+qsJC4GPkkGUS5CkmS+Y9r11bc
ueRjKkVFrnwhwYSM+IMqLCTCxcgnySDKRUhczH+ShMTlXFyuh4pcXELi8rtWdxMy4g+qtJC4GPkk
GUS5CImL+Y+LkCSdi8v1UJGLT0hK3YSM+IMqJSRRuBj5JBlEueBi/uNC0rnkY0xERa78Y5eqCRnx
B9VCSICKTBIBYgAQEkBIgPgDhAQQEiD+ACEBKjJJBIiBUhMSzXAJe9ir2Kgq50lFLuzYGKsRf1AF
hSQN86iKoKqcJxU59+m/fjBWI/6gyIUkzGAKIaEiV9SxMVYj/qAaCInLmlcICRW5Mo+NsRrxB0Us
JFEGU16CjjKmEnHGQEmmQn379rV+Eh7aR8efPn16VreCDIa01HeDBg2swVCHDh3s8hRBIYk7Tyhu
IcFYjfiDKi4kcQZTccZU3jZRxkBJpkISBBkG+StbcOlvrbWkJShU6bVsuCpv0GDI5TyhuIUEYzXi
D6px11aSMVWYMZCrqVCSkGj5Ca2R5C/H6xLw31m6nCdUHSHBWI34g2omJEmLLoZt42oqlCQkH3/8
sf178uTJZSpgsEWSdJ5QdYQEYzXiDxASZ1OhJCHRQnv6WzNrEJLSERKM1Yg/qKJC4mIw5SokrqZC
nTp1Mj179sz8PWvWrDItGfVvaxDTY8GCBba7CyGpvkKCsRrxB1VUSFwMplyFRLiYCg0fPtw0bNjQ
Nv11B9e0adPQwXb1a/fr18+OlWj2jSqg36cbIaleQiIwViP+oAoKiYvBVC5C4mIqpBlehx56qA2s
Jk2aZMZE/EKigcphw4ZZAdHd4z//+U9bYe+9916EpBoLCcZqxB9UQSHxSMtgysPFVMg/4ysJtWh0
DTNnzuTXrEZCEgXGasQfVEEhKTbUOlHzX11kDzzwgJ0Z06JFi7zc7qDqCQkQf4CQFIwe6urVq5cV
EA2KDh482Kxdu5ZfEiEB4g8QEkBIgPgDhASoyCQRIAYQkjgqwngHUyqEpKrHRkWeZ3WoLwhJiQlJ
RUxPZAl4hKSqx0ZFnmd1qC8ICUISS5hJEEJCRXY5NsZq1es7QUgQkryFxMUkCCFBSFxjp9SFpCp/
JwhJiQqJi/HOlClTTPfu3a1xj57lkLeCR5RJUNw+/oqhJ331uZ76HTBggF2K3uW4YsWKFaZ37952
X20zYcKErOuKMxxCSCr/2KVorJZ0foV8J66GX8HvDCGBgoXExXhHwa3lJeTvMGLECLscxPr16+1n
USZBcft4FeOAAw6wFUnGWKowWlvLLwZJZcjjpHPnzmbp0qXWX1sLO3okGQ4hJJV/7FI0Vks6v0K+
ExfDr7DvDCGBgoQkH+MdJXKVNW3aNOeurbB9FNSHH364XUrFQxXotNNOcy5Dd2Z6aDG49ISL+RFC
UtxdW9XRWM31/PL5TlwNv4LfGUICBQtJLsY7ujtSq0BBHjSdihKSuH3C+nz/9re/mZ122ilLGOLK
0MrBuptTt5fuwjxczI8QkuIWkuporOZ6fvl8J/kafiEkULCQuBjvaG0r3fU3atTI3o3JtCdJSFz2
CQvqkSNHWmHQ/i5liIULF9qludXtoP2Fi/kRQlL9hKTYjdVczy+f7yRfwy+EBAoWEhfjHfXR+lfd
VZM6mNCDJkEu+4QFddeuXe0Ao2sZfoYOHWorlpKCi/kRQlIcxy4lYzXX88vnO8nX8AshgYKFRCQZ
72gwT3f7GgRftWqVHYRUWZrF4hE0CXLZR0GtCuTNlHn++efteI23jetxNXNL4qFFHdu2bZv5LMlw
CCEpjmOXmrGay/nl+53kY/iFkEAqQuJivKMZVepyqlmzpjWbkhGQAt1rNoeZBCXto6DWYKD6cjUN
skaNGnYbv59DUhmq3FtttZUVoJYtW9rK6W9ZxRkOISTFcexSM1ZzOb98v5N8DL8QEkhFSDySjHdU
AfwGQGolBAmaBMXto1lYuiMTX3/9tfnhhx/yOq4+W7NmTeR5p2F+hJCU/7FLzVjN5fzy/U6KNeYR
khIQEkBISCL/D4zViAFASAAhKQiM1YgBQEgAIQHiDxASQEiA+AOEJA8wvEJIgPgDhKQgXKYosgQ9
QgLEHyAkBYnEY489Zh566CF+VYQEiD9ASGhtICRA/EGVF5JCzKGSjKfizIe01ISWptDTt1qYUUtV
+IXExdQo+HfcPi5GRVTkij92UvylYVKVTxwmxX7ceQNCUnJCUog5lIt5VZiRjiq+lkQZNWqUfW/G
jBk5mxr5Wy0u+7gYFVGRK/7YcfGXlklVPnGYFPtx5w0ISckJSVrmUFHmVUEjHZWru7+OHTtGdm25
mBoFhSRuH1ejIipyxR87Kv7SMqnKJw5dYj/qvAEhKUkhKdQcKlfzKq9c/yqqQSHJdcG+pH1cjYqo
yBV/7Kj4S8ukKp84dIn9qPMGhKQkhUTkYw6Vr3mVV27UsyLlISSuRkVU5Mo5dlj8pWVSlU8cuhqj
hZ03ICQlKyQeuZhD5WtepW4mlSt/9ooSEuFiVERFrtxj++MvTZOqXOMwV2M0/3kDQlKSQpKvOZSr
eVXYVN4hQ4ZYjxENXqrfW3eAugMtTyFxMSqiIlf8sePiLy2TqnziMMkkKu68ASEpOSEpxBzKxbwq
rAKrYmpMRcfVSwOo3tTh8hISF6MiKnLFHzsu/tIyqconDpNiP+68ASEpya6tQsyhXAyv4o6bZO5T
XqRtVERFzv/YSfGXtklVLnEYF/tJ5w0ISUkJSSmAURFPtgNCAghJQWBUhJAAQgIICSAkQPwBQgII
CRB/gJAAFZkkAsQAQgJUZJIIEAOAkABCAsQfICSAkADxBwgJUJFJIkAMICRARSaJADEACAkgJED8
AUICCAkQf4CQABWZJALEAEICVGSSCBADEPob8kNSiTkH4LeHgoWEH5RKzLkAvzkULCTeD8urdF7F
mFh4EX9QxYWEOyMA4g8AIaEiA/EHgJBQkYH4A0BIqMgAxB8gJFRkAOIPACGhIgPxB4CQUJGB+ANA
SKjIAMQfICRUZADiDwAhoSID8QeAkFCRgfgDQEioyADEHyAkVGQA4g8AIaEiA/EHgJBQkYH4A0BI
qMhA/PElAEJCRQYg/gAhoSIDEH8ACAkVGYg/AISEigzEHwBCUjUrMi9elfkCQEiAO2oAQEgAEBIA
QEgAIQEAhAQQEgBASAAhAQCEBAAhAQCEBBASAEBIACEBAIQEEBIAQEgAEBIAQEgAIQEAhASKT0BY
MwoAqPmAkAAAQgLFISYAgJAAICQAgJAAQgIACAkgJACAkECpiQkAICQACAkAVH8hwdubFy984AEh
4a4XgDoDCAkVAgAxAahCQkJFAKAOAUJCJQCgDgFCQiUAQEgAEBIAhAQAIalYVqxYYTZs2BC7zS+/
/GLWrl1bLYLh2muvNTNmzCi38pctW2auueYac8YZZ5gpU6ZQ+xASQEgqtxKMHDkycv78b7/9VtA+
jz/+uGnWrJnZfffdzbbbbmu6du1qfv/996yyRo0aZTp06GBq1aply60O7L333ubWW28tl7I3b95s
dt55Z3PHHXeY2bNnm7fffpvah5AAQlK5leCdd94xd911V9brtNNOM/Xq1SuT9HPZZ/369Wb77bc3
EyZMsH9/+umnpmbNmuaVV17JKqtHjx7m9ttvt2KDkCQzd+5cs+WWW5qNGzdm3nvhhRfM6NGjqYUI
CSAkxVEJ1MV04IEHmvvvv9+57LB95s+fb7bYYgvz3XffZd7r2LGjuemmm0LLaNiwIULiwMSJE61A
+7nwwgtN+/btqYUICSAkxVEJ7rnnHtOyZcvIbi3Xfb799luz1VZbZe6Uf/jhB7PLLruY999/vyAh
ufLKK82ll15qnnjiCXPwwQfb1pDQsTVusOeee5o99tjD3HjjjVn76XN1BzVt2tRst912plGjRuaZ
Z57JfHbzzTdbMaxdu7Zp166deffdd52Pe9VVV5n69eub/fbbz4wZM6aMkGiMqHfv3ma33Xaz5+a1
0sLQmEf37t3tdi1atDDjx4/PfPbQQw/Z61OL5JBDDrFjJHfffbft6pK46L3LLrvM6fuIuh5ASAAh
KagSKPnvuuuuZs6cOc7lxu2j8Q8d95JLLrHJ2Z8U8xWSs88+2+y///7m6KOPNo888ohZsmSJfV8D
3AcddJB57bXXzFNPPWV23HFH8+yzz2b2u+6660yNGjXsOWkfDYZ/9NFH9rPrr7/eJmN1saklpWNo
TGf58uWJx9W+un5dm8rr06ePbYn5hWTgwIGmc+fOZunSpbZrasGCBZHXJ2EYN26c7QocMWKEPQ91
E4ovvvjCXHHFFVYINT7y3nvv2XM85ZRTTPPmze173jUlfR9R1wMICSAkBVWCIUOGmBNOOCGncuP2
Wbhwob0LVzLUv1GtkVyFRHfZX331Vea9n3/+2d6RKwl7nHzyyeass87KfK7kq661IJs2bbL7Dho0
KPOeBrSVeCUAccdVl16dOnVscg92bd1yyy2Zv9u0aWN69eqVUytPSED0u02bNi2ra2uHHXaI7dpK
+j6irgcQEkBICqoEn3/+udlmm23MvHnznMuM2+eTTz6xA+gvvvii+eyzz+wds5L59OnTCxaSU089
tcyxdH1HHHGEOf744+1LyfyYY47J+lxdW0EWL15sP9Ndux+J47HHHht7XE3D1b5PPvlkGSHxt0jU
hSYxVVeVWghJqGWh1ogEQuVPnjw5JyFJ+j6irgcQEkBICqoE559/vmndunVOZcbtc/XVV5uTTjop
87dmGakb5cQTT0xdSD788EN7fepmUtL2Xt4MMe9zJeEgH3zwgf1MguenW7du9nzjjrto0SK776uv
vhorJF7rTN+Hur2irlMz3tRy0fiNWjQ6/3yEJOn7QEgQEkBIUq8EajFo/ECDua4k7aNuJD034kfj
FJoinLaQqCtHLSONxYTx008/2c81lhBED0pq8FpjCn7q1q1rzjvvvNjjKvGry84vGjqX4Ht+hg4d
aicdhHVzaXxDv9PMmTMzXWcuQtK/f/8sQU/6PhAShAQQktQrwQ033GC23nrryKfPNWVX3Tw//vij
8z5KmPpcg9dCffGNGzfO6qf3Wioqt0GDBvYOWv9XAs01AaoFpAFzPQQp4dC0Y//MK43l6DkWDThr
DER37WqNiAsuuMCemyYM6Ho0g0vf11tvvZV4XF2P9lWrRNeqVocervSPkUyaNMnO3JJ4DB482LRt
2zb02tRVqBaLZnWtWrXKXpPOQzPB4oRE5avbcPXq1c7fB0KCkABCkmolUGLz958H0dRV7a8pvK77
SBD69etn7+zV2lDrRa2Ur7/+Omu7vfbaq8zT8Wq55Cokugu//PLL7ViEBpqVWLWtv1WiLiBNSdZL
g+neLDIl2TPPPNO2TCQCajE8+OCDTsdV95am/eq81RKZOnVqma4tDbbrmBqY1zTpuFlxmr6ra5Do
DRs2zFx00UX2WrxuqTAhWbdunWnVqpVthWh7l+8DIUFIACGp0EqgVoOSZT7oLlyztTR1tSL49ddf
7Z29/o3q5lq5cmXoU/sSv6jPktD1xc3K0nHXrFnjVJaETdt7qHXiwpdffpm1n8v3AQgJICQVUgn0
xPptt93GrwwICQBCkh/Bu1wAhAQAIQEA6hAgJFQCAOoQICRFWgnKy5hJM6HCHgqEyqe8zbgQEoAS
E5LyWgY9OOWUKajFQ3kufY+QACAk5SYkjz32WE5P08eBuRNCgpAAQlKCQpImmDshJAgJICSVVAlc
jJn69u2b9bS59pGJkn8lX88oSU92a5VbPeU9YMAAu0x7lJB4+/jLjTKfijN8ytfcKRfDqXwNtbz9
9GT6UUcdZZ/k13esBwS1TL3WHuvSpYv1KvF/D3FGW1oxYPjw4VnH0edHHnmkfXjUxeQr6TcHhAQQ
EudK4GLM1KFDB/u+PxEFl16XSBxwwAE26ckoSclca235k3PSGEmc+VSc4VO+5k65GE7la6il/bQW
1x//+Ef7uRZS1HIpf/rTn6zQqktOS8hoLTD/bxJntKXvVOLnf1pdZckx0eWcXH5zQEgAIXGqBK7G
TK5Ccvjhh2ct7KjkftpppzkJSZz5VJAww6d8zJ1yMZzKx1DL208LUnrLo3geJn/961+zBE1CI1yM
ttauXWtF2rt+nYeER38nnZPrbw4ICSAkTpXA1ZjJVUiC4x9/+9vfzE477ZRJ1HFCEmc+5RFn+JSP
uVMuhlP5GGqF7af1sLTP66+/nnlPrRGdg3A12lJ3mERQaFt1YUlwks7J9TcHhAQQEqdK4GrMlK+Q
yF9EidpbBDFOSOLMp1wMn/IxdxIuhlNR15ePgVSSkLgabWl5eLU8tOy9RMVrYSSdUy5mXICQAEKS
WAlcjZk6depkevbsmfl71qxZTkIiYysNfrt0bcWZT7kYPuVj7uQnznAq6vryMZBKEhJXoy1tJyG5
88477ZiLNy6UdE75mHEBQgIISWwlcDFm0gwhDQirW0R3t5pVFSYkSnbeTK7nn3/e9sX7TZmSBtuj
zKdcDJ/yMXdyNZyKEhKXY+QqJMLFaEuolaYWnzxOcjknl98cEBJASJwrgYsxk2YoHXrooXabJk2a
mI8//jhUSNQiUJ+8pqxq9pVMlvwzi5KEJM58KsnwKR9zp1wMp/I11MpHSFyMtoQG11XW2LFjczon
l98cEBJASHKuBEnGTMI/Yyku0Wo7v5tirkSZT7kYPuVq7pSL4VQc5WEgVYjRlss5ufzmgJAAQlJh
lYB1swAhAUBICkIOisEnqAEQEgCEBACoQ4CQUAkAqEOAkFAJAKhDgJBQCQAQEgCEBAAhAUBIAIA6
BAgJlQCAOgQICZUAACEBQEgAEBIAhAQAqEOAkFAJAKhDgJBQCQAQEoA/UBEAEBGAai8kVAgA6gwg
JKlVDF68eLm9ABAS4M4XABASQEgAACEBQEgAACEBhAQAEBJASAAAIQGEBAAQEgCEBAAQEkBIAAAh
AYQEABASQEgAACEBQEgAACEBhAQAEBJASAAAIQGEBAAQEkBIAAAhAUBIAAAhAYQEABASQEgAACEB
hAQAEBIAhAQAEBJASAAAIQGEBAAQEkBIAAAhAUBIAAAhAYQEABASQEgAACEBhAQAEBIAhAQAEBJA
SAAAIQGEBAAQEkBIAAAhAYQEABASgLwEJPgCAIQEACEBAIQEKkdMAAAhAUBIAAAhAYQEABASQEgA
ACGBUhMTAEBIABASAEBIiiGh8iqdFxD3xD1Cwl058JvzHUAKvzlRQGUCfnuuHQr67YkEKhMQA1wz
FBQDRAMVCogBrhkQEioUEANcMyAkVCggBrhmQEj4MiuaFStWmA0bNsRu88svv5i1a9dWi+/62muv
NTNmzCAGSviaf/31V7NkyRLz+++/R27zww8/mMWLF5vffvuNuEdIqnaFGjlyZOQ87KgAd93n8ccf
N82aNTO777672XbbbU3Xrl3LVKxRo0aZDh06mFq1atlyqwN77723ufXWW0mqJRr3Tz/9tNlpp53M
nnvuaWP/rbfeyipHdeCvf/2r2XLLLU39+vVNnTp1zLRp04h7hKTqVqh33nnH3HXXXVmv0047zdSr
Vy/ybspln/Xr15vtt9/eTJgwwf796aefmpo1a5pXXnklq6wePXqY22+/3VY4hAQhqepx/+GHH9o4
f+211+zfDzzwgBWKdevWZQlN7dq1zcyZM+3fo0ePNltvvbX517/+RdwjJNWjia8upgMPPNDcf//9
zmWH7TN//nyzxRZbmO+++y7zXseOHc1NN90UWkbDhg0REoSkysf94MGDTadOnbK2O+CAA8zYsWMz
f+tztc491A2mm64bbriBuEdIqkeFuueee0zLli1z6rcN2+fbb781W221lb3bEuoP3mWXXcz7779f
kJBceeWV5tJLLzVPPPGEOfjgg+1dodCxr7nmGtudsMcee5gbb7wxaz99fscdd5imTZua7bbbzjRq
1Mg888wzmc9uvvlmmxR0p9iuXTvz7rvvOh/3qquusl0U++23nxkzZkyZCqUxot69e5vddtvNnpvX
SkNIql/cKwaCsffnP//Z3kR5NGjQoMwNlcTl2GOPJe4RkqpfoZT8d911VzNnzhzncuP20fiHjnvJ
JZfYIB0/fnxkOa5CcvbZZ5v999/fHH300eaRRx6xA5pCA30HHXSQ7VJ46qmnzI477mieffbZzH7X
XXedqVGjhj0n7aNBwY8++sh+dv3115udd97ZdrGpJaVjaExn+fLlicfVvrp+XZvK69Onj22J+SvU
wIEDTefOnc3SpUvN3LlzzYIFCxCSahj3Sq66efrv//7vrG01HqJk7XHIIYeYs846K2ubk046ycYX
cY+QVPkKNWTIEHPCCSfkVG7cPgsXLrR3IwpO/RvVGslVSHT39dVXX2Xe+/nnn23XwN1335157+ST
T85UVn2uuzH/XaHHpk2b7L6DBg3KvLd582ZbIVUR4o6rrg31f19xxRVlmvi33HJL5u82bdqYXr16
VfrsHISkfOP+P//5jz3e//zP/2S9/1//9V/2jt9DyV9J+IMPPrB/v/7663bgXeOExD1CUqUr1Oef
f2622WYbM2/ePOcy4/b55JNPbMV48cUXzWeffWaaN29ug3r69OkFC8mpp55a5li6viOOOMIcf/zx
9qWgPuaYY7I+VxM/iKZf6jPdzflRkvB3NYQdd9myZXbfJ598skyF8t+ZqStBYtqiRYvMICxCUv3i
XslZd+UPPvhg1vvDhg0z++67b+bvjRs3mlNOOcVuq7v91q1bm9NPP93GL3GPkFTpCnX++efbgM6F
uH2uvvpq21z3Vx41j0888cTUhUQzZXR9am4reL2XN0PM+3zixIllytNdoT6T4Pnp1q2bPd+44y5a
tMju++qrr8ZWKK91pu9DyaOyJhUgJOUf93Xr1rVdRX769+9vWrVqVWZb3WAphjTjSy0JiQlxj5BU
2QqlgFY/6kMPPeRcXtI+ak77Z6YI9ddqqmTaQqImvO4QNRYTxk8//WQ/111gED0oqW4FdTcEE8J5
550Xe1wlAHXZ+SuPziX4np+hQ4faSQeV0dxHSMo/7s855xw7JdiPnqUaPnx4ZJma2ajW+pQpU4h7
hKTqVihNO9Q89qinzzXDRM3dH3/80XkfBY4+1yCeUB9r48aNywwyqqWicjWTRXdW+r/6YHOpUF4L
SAOHeghSFUiV0z8DRX3amt+vgUj1BetuzeujvuCCC+y5aeBU16OZLPq+/A+SRR1X16N9dXema9Xd
lx6u9PcVT5o0yc5gUSXS9NC2bdvSIqmmca9BZYmCNx6oFoLibuXKlZltNJby/fff2/9r6q/GEQ47
7LDYJEvcIyRFX6H0A3v9qmFoCp/21xRe131U+fr162fvcNTa0F2cWilff/111nZ77bVXmaeE1XLJ
tULpjujyyy+3fbIaRFRl1rb+u7MLL7zQzqrRS4OK3iwyVb4zzzzT3qGpMujOKdjPHXVcNfM1/VHn
rTuyqVOnlmnia9BRx9QApaaL5jI7CCGpWnEv1JWkOFKi1SD7yy+/nPX5fffdZ2NNs60UE6oX/gcW
iXuEpEpWqCTUalDQ5IPuRnR39sUXX1TIdeoOT4Oh+jequa+7w7CnlyV+UZ8loeuLu6PUcdesWVNl
Y4C4zw3Fku78o+JQ68qp5fDNN98Q9whJaVQoPbl722238SWWcAwQ91AdYgAhqcQKpbsKQEiIe0BI
+DL5EogBrhkQEqBCATHANQNCQoWqFIrVdIcYqJ7XrNlPYQ8CVkbclnrsIyQkkdQo1iWuiYHCrynu
uirrmqOmzVZG3JZ67CMkJBGEhBhwEpLgCyEh9hESkghCUo4xEJV8q+sLIUFIEJJyFpI485k4U5xC
jHbiPvfKfeONN+yTsfvss0/Wsguux0gy3SEGSrtFEhdDekhQizL6zae0vIjWrPI/+R1XP4JC0rdv
36wVG7SvfEn8q2G7xC2xj5AUZRKJM5+JM8XJ12gn6XOVKxMgLXQ3btw4u7aRzl1P7bqW4WK6QwxU
LyHJ9ZqTYujRRx+1S4fMnj3b/i3B0A2TliRxrR9+IenQoYONQ3/CDy7j7hK3xD5CUpRJJMp8Js4U
x6so+RjtxH3ulas1fz799FP7txZw1CJ5Wp/IpQxX0x1ioHSv2SUOxbnnnmtbxFrKZIcddjBvvvlm
TvUjFyFxiVtiHyEp2iQSZT4TZ4oTVlH8+yQZ7UR9HlWuhEWtE5cyXE13iIHSvWaXOBTr16+33VVa
iv3iiy8OLcO1fiQJiUvcEvsISVEnkTDzmThTnKiE72q0E/W5i5AklZGL6Q4xUJrX7BKHQr7sapGo
XowdOza0DNf6kSQkLnFL7CMkVSKJ+M1n4kxxohJ+ktFO0ucuQpJURj6mO8RA6XVtJcWhUJdvly5d
bLeQurE+/vjjzGe51o9OnTqZnj17Zv6eNWtWlpC4xC2xj5AUbRKJM5+JM8XJ12gn6fMkIXEpw8V0
hxgo7WtOiiHNRpSXjpZAV4LWWMihhx6atZBjLvVDDony5VH3k1oRmukVHGx3iVtiHyEpygoVZz4T
Z4qTr9FO0ucuQpJUhovpDjFQ2tccF0Py2FCyfu655zLbr1692grLgAED8qofmtUlIdL5NGnSxLZu
gkLiErfEPkJStEkkyXwmzhQniiSjnaTP0zhGkukOMcA1pxGHudQP/yzHKFzilthHSEgiQAxwzYCQ
UKGAGOCaASGhQgExwDUDQgJUKCAGuGZASKhQQAxwzYCQUKGAGOCaASGhQgExwDUDQgJUKCAGuGZA
SKhQQAxwzYCQUKGAGOCaASGhQgExwDUDQgJUKCAGiHtASKhQQAxwzYCQUKGAGOCaASGhUgG/PdcO
1eC3JxKoVMBvzncABf3mREHKXzCv0nkBcU/cIyTAXSkApJED+AoAIQEAhAQQEgBASAAhAQCEBBAS
AEBIABASAEBIACEBAIQEEBIAQEgAIQEAhAQAIQEAhAQQEgBASAAhAQCEBBASAEBIABASAEBIACEB
AIQEEBIAQEgAIQEAhAQAIQEAhAQQEgBASAAhAQCEBBASAEBIACEBAIQEACEBAIQEEBIAQEgAIQEA
hAQQEgBASAAQEgBASAAhAQCEBBASAEBIACEBAIQEACEBAIQEEBIAQEgAIQEAhAQQEgBASAAQEgBA
SAAhAQCEBBASAEBIACEBAIQECCKEBAAhAUBIAAAhAYQEKu3351U6L4QEEBLgt4fUf3OiAEgmwO8O
Bf32RAKQUIDfHAqKAaIBSCrAbw4ICZBUgN8cEBIgqQC/OSAkQEABv/n/5auvvjJr1qxJLOeXX34x
a9eudTrmsmXLzDXXXGPOOOMMM2XKFKd9HnzwQTNx4sTIvwEhAYQEiuw3V5Lef//9Tf369U3NmjVN
mzZtzIwZM8psN2rUKNOhQwdTq1YtM3LkyMTjbd682ey8887mjjvuMLNnzzZvv/2203meffbZ5tRT
T438GxASQEigyH7zBx54IJPkV69ebY499lgrKr/++mvWdj169DC333672X333Z2EZO7cuWbLLbc0
GzduzOk8CxWSF154wYwePTr176+8ykVIACGBavebP/zww3bbTz/9NPTzhg0bOgmJWjrbb799zudZ
qJBceOGFpn379ql/f+VVLkICCAlUu9986tSpdtsvvvgibyF56KGHzJ577mlbJIcccogdIxF9+/Y1
1113XWa73377zX4+ffr0VITk7rvvtt1pEjCVe9lll2WOo7EandMee+xhbrzxxsw+33zzjWndurW5
6aabMu+pW+6UU06x4zNx5SIkQFIBfvOIFkGzZs0iP3cREonQFVdcYbbbbjs7PvLee+/Z9zXG0qdP
nywh0Xk99dRTqQjJ8uXLrQA0b97cHvejjz6y71977bXmoIMOMq+99po91o477mieffbZzH6PPvqo
FT3tIzSuc/DBB5uff/45tlyEBEgqwG8e4P777zd16tSJTZS5dG3tsMMOWe+Vt5CIYBeUxEAtCbUq
PE4++WRz1llnZe137rnnmn322ce8++679rzffPPN2HIREiCpICT85gGeeOIJ230zZ86c2O0qW0iO
OeYYc9RRR5V5ffvtt6EJ/5NPPrHHOOKII8zxxx9vX3vvvbctx8/69etNo0aNzDbbbGMuvvjiRIFC
SICkgpDwm/t46aWXbNL3unaKWUhefvlle77Bl55vCUv4H374oT3G9ddfb5555pnM65VXXsk6NwmR
WiRbbLGFGTt2LEICgJCA62/++eef266f++67z6mcQoSkU6dOpmfPnpm/Z82alXrXVv/+/e3guYe6
ttTKuOSSS2L369Wrl+nSpYu55ZZb7NjOxx9/HFsuQgIkFYSE3/z/58wzz7QJ/4033jDz5s3LvH78
8ces7fQ8iN5r0KCBvbvX/71WgKuQDB8+3AqRnnhXq6Bp06apC8mkSZOsEOiZGI+rr77adts9/vjj
5qeffjLfffedHQvxULde3bp17ZP9v//+u+nYsaM59NBD7bZx5SIkQFIBfvP/Q5MmTUJd9T744IOs
7fbaa68y2/in8roIyZIlS2yC1r46ru760xaSdevWmVatWtlWyEUXXZRplVx++eVm2223ta0vCYLK
FZphJpF57rnnMmVILCQsAwYMiC0XIQGSCvCbVxJa16u8+fLLL7NaFEJP66srL/jUfqHlIiRAUgF+
cyi5GCAagKQC/OaAkABJBfjNASEBkgrwmwNCAgQU8JtXDuVtWJWPqRZCAoCQQCX/5rlM1S1Pw6p8
TbVc0QOZYVOm9dLT+ggJVPtkEnwBQpIPYUZPjz32mF1CvrKFJF9TLVfeeecdc9ddd2W9TjvtNFOv
Xj37QCNCAggJICQOFLr2VHkKSb6mWvmiJ/wPPPBAu3pyVYkBaj6kJiaAkGj8oHv37tbwqUWLFmb8
+PFZn1955ZXm0ksvtcuIyKNDd99RRk/eth7q5lH3kpZC0dPkWl1XS6OECUmc+ZRYsWKF6d27t9lt
t93s5xMmTAi9nihTLZV/880324Rfu3Zt065du6xlUqKu1YV77rnHtGzZsqi7tRASQEig3IREojBu
3DhrrTtixAi7jIiWVPe3HPbff39z9NFHm0ceecQucxJl9BQUBy2hUqNGDTNq1Ci734wZMyK3TTKf
GjhwoOncubNZunSp7bpasGBB6PVEmWppfTCJn3zn58+fb4+va9W1xF1rElo1eNddd01cfh8hAYQE
qq2Q+JGAaLtp06ZlJVfd4QeXNQnr2vKLg9a3UjLXAohhBLdNMp9q06aNXaHX5a4/uM7Xpk2bbPmD
Bg3KvKcBeYmVBCrpWuMYMmSIOeGEE6pcDFD7ASGBVIVEd+5qjUgctN3kyZNDE34uQuIZSqlrK0lI
XMyn1CWmFoS639RqyUVIFi9eXGZxSCEBOPbYYxOvNQqt26VFHLVaMkICJBUoyd9cM4x0l6+xC/lw
yOwpLSHxDKWinhUJ2zbJfGrhwoXmpJNOsuZTcZ4oQSHRSsYq/8UXX8zarlu3brYbK18hOf/886uU
RwlCAggJpP6ba7xC78+cOdP+rdlHrkISZvTk31Yr5OpuXWMpSULiaj7lMXToULPLLrtEdnMFhWTD
hg128F3jMH60VPx5552Xl5B89tlndvzHdbozQlIi3Ty8qv8LISnbNaO7e82AWrVqlTWA0nZjxoxJ
TK5hRk/BbTV+ULNmTTtorjEJtTw8n5PgtknmUzqeZm5JPAYPHmzatm3r3CIRF1xwgWncuLEdFJew
aAaXrvWtt97KS0huuOEGs/XWW9uyEBIqFvCbl/S1a+quxh6U8IcNG2ZNmyQQXrdSVHINM3oKbitB
UBfYVlttZV8a3PamFwe3jTOfEhpsVxl16tSxU23jZkmFCYmESW6QapnUqlXLtmi0TEtUKykJCZl/
DAchoVIBv31JX7eSrN+sSa0TV1yMnvT5ypUrnZ76jjOfUjmywy0EWQS7nkt1jgEyIIkEiAGuGRAS
KhQQA1wzICRUKCAGuGZASPgygRjgmgEhgUqpUFpCIZdBv3xMdoLGP+VtBEQMcM3liZ7h0FpbgJBU
6wrlYlajRK5F3erXr2+nS2pKYlLlyNdkJzgVsTyX3SYGuObyRkue3HrrrcQzQlK9K5SLWc0DDzyQ
EQI9iKV1eiQqYVMVPfI12SlUSMKMh9KgvMpFSIrvmtP8rYNCkosJFiAkVbZCuZjVPPzww7Y8LcEd
Rb4mO4UKSaHGQxVdLkJSfNec5m8dFBJASEqiQrmY1UydOtWWJw+EMKJMdvr27Wu9Gjx0DH0+ffr0
VIQkyngozjzom2++sWsn3XTTTZn31C2ntZK8J4CjykVIqu41RxlGRf3WLrGr96666irbWt9vv/3s
kitBIQkzwUrD2AoQkqJJIq5mNUruzZo1i/w8ymSnQ4cOpk+fPlmVKLjMdSFCEmU8lGQe9Oijj1rR
0z5C4zpyitPyFXHlIiRV95qjDKOifmuX2NUqvqo/Wg5F+2l7rekVN0aSlrEVICRFk0RczGrU5aV1
f5KSadi6P+UtJGHdEi7mQeLcc881++yzj10wT+f95ptv0rVVjeM+zjAq7LdOil11Cate6AYq2LWl
perD4jltYytASCo9ibiY1cjTWc1+F3vN8hISLRh31FFHlXmpNRWWBFzMg4Rc8uRPoe/g4osvdkou
CEnVveY4w6h8hERT3fX3k08+WUZIolokaRtbAUJS6UkkyazmpZdessLgdf9UlpC8/PLL9lyCL90R
hiUBV/MgCZFaJOqKGDt2LEJSAnEfZRiVj5AsWrTI/v3qq686C0naxlaAkFRqhUoyq1FrRU3w++67
z/l4YULSqVMn07Nnz8zfs2bNSr1rK2g85GoepO6DLl262G4Ije18/PHHseUiJNXnmoOGUWG/dVLs
aqq8BsT9oqHYC75XnsZWgJBUaoVKMquRn4FE4Y033rBdX95LS1PnIiTDhw83DRs2tN0AuvNq2rRp
6kISZjyUZB6kLju5xumpfSWEjh07mkMPPTRrmfCwchGSqnvNcYZRYb+1S+xqbEMmUmqVzJ8/37Yi
5AESNUbiEpu5GFsBQlKpSSTJrKZJkyahT757rm+uQrJkyRKboLWvytRdf9pCEmY8FGcepBlmqsjP
PfdcpgwlEAnLgAEDYstFSKruNccZRoX91i6xq+4tTfvV+2qJaJp80pPtaRpbAUJSUklEa3aVN2HG
Q3HmQYWUSwxUzWtOMowK+61dYlc3J7l2P5W3sRW5DyEhiQAxwDUDQkKFAmKAawaEhAoFxADXDAgJ
XyYQA1wzICRQTSoUhlWFkY9hEkJS9eI7DWOsyjbXquy6jpBUsQqVy1RdDH4KI5/lyRGSiiOt+E5j
GfryXMre5Toru64jJEVcocLMf3Ix7UFIEBKEpOoLSbDOh+UFhIQKFUmha08hJAgJQlL1hcQlLyAk
JVChpkyZYrp3725Nc7TCqLwU/HhGPFpGRB4dsuKNMv8JM+2Rt4eWk9ATu1pdV8tLhAVXmgY/SdcU
V1bcZ4WcYyHluhgmISS5XXOhZme5xndaxljlHSsyodM+Hjo/nafnKSR0TG/ZF3+dj8oL3nehJZb0
pL4WR/UvG4OQVIMKpR9/3Lhx1jZ3xIgRdqkGLanuv5vYf//9zdFHH20eeeQRu1RElPlPsPKo4mgx
yFGjRtn9NOAXtW2aBj9J1xRXVtxnhZxjIeW6GCYhJLldc6FmZ7nGd1rGWOUdK3/5y1/Msccem9XC
0Hn6E7/WHNMq3MHrjMsLsu+WGZ7qpdb2U5l6kh8hqYZNfCVbbTdt2rQsIdHdT3BpiKQmrCqc7tK0
AGJS0788DX7CrimurKjPCj3HfMt1NUxCSNyvOQ2zs1zi20VIXH7nioiVF198MWsBV12/ruPEE0+0
f2s9MYnXpk2bQq8zKi9o1WLd2HnnqWPkspo4QlIFhER3D7pz9+4+Jk+enNi/mSQknmmP7uSSKlp5
GPzEXVNcWVGfFXqO+ZbrapiEkLhfcxpmZ7nEt4uQuPzOFRErWtFb16sbL/mlaN/XX3/dCqkEQH4o
Wg086jpdx0gkLGqdICTVoEJpyXTdJauy6I5FhjppCYln2hM1f7y8DH5crimprLDP0jjHfMp1NUxC
SNyvOQ2zs1zi20VIXH7niooVCZS6uLSPvFm81tdbb71l/vjHP9qZWggJQpJBfZh6f+bMmZkmp6uQ
hJn/+LfViqW6s1GfqUvXVloGPy7X5FqW/7M0zzGXcl0Nk0pVSDxLg1y7tgo1O8slvkUaxlgVFSs3
33yzHSw/7rjjzPPPP2/fUxeeWmU6vmdrHXadSXkBIamGQqLBLt1taQbRqlWrrMmOtvPP2ogSkjDz
n+C2Q4YMMTVr1rSDgZr1ojsqz8OkvAx+XK4pydQo6rNCzrGQcl0Mk0pdSIKvpGtOw+wsl/hOyxgr
jVjRbDQNqEcZ0/3jH/+w56buLG8biYt8UdSyihMJl7yAkFQzIRGaoqe+e1WIYcOGWSMfBYLXXI4S
kjDzn+C2CnQ1dRWAemmQzpuKW54GP0nXFFdW3GeFnGMh5boYJuUSA1HJt7q+wkjD7CyX+E7LGCuN
WNE0dH3+ww8/xLZsJEIe77zzjt3nnnvuiRUSl7yAkFRDIRG6q/HfaelO3hUXoyd9vnLlShugSaRl
8JN0TXFlJR0n33MspFwvwRXi102LJPfv3IVc4jstY6xCYmXjxo1WbMqTYjKAQ0gqSEiAGKjqQkLc
u3P//feb2267rSTjnmggiQAxwDWnQFW1ikZIqFBADHDNgJBQoYAY4JoBIeHLjEBTErUQnBZs04KH
FUl5mN7kU2YpGG0hJICQQLlUKM1/11RHLfWgZUXefvvtCj2v4NTAfJaczqeMpH2q4zL3CAkgJFAu
FUor0WqVU00JrAyCCTsXc6yofVxEIGkfF8MekirXDAgJFer/oO4cPdhUWZTHnX8arZoghRp5kVS5
ZkBIqmWF0h23lohXi0Rr62iMROhBJi2JIA+B2rVrm3bt2mUtwyDCDK/CSDLiCSbwoDmWut5k1KP9
GzRoYJc60TINWoohah+vTD3Vq9V29ZSunkj2lr6O2yfs8zDDHi3A5z2566HVWQ877DBrjERSLe5r
jorfpHgtxDQtl3oVZwKVi8kbICTlXqH09Ku8C7TMgsZHPBc0rS6qxHn77bfb9XqUZLUkg4xr/Ik3
aHgVRpIRT9LYhNYW0rIiSuZK1KpkQaOesDIOOOAAW1F1bkr88j/wV7hcxkjCDHvuvfdeuwyEXzS0
9pLn24CQFPc1R8VvUrwWYprmWq+STKByMXkDhKTCura0OJuH7tp15z1o0KCsVoEqlALYH/Bhhld+
XAyE4hK4HpzSgnP+cxFBo56wMg4//PCsRekkBKeddlpeQhLWtSUBURLwZnppleF69eqV8YJASIpX
SILx62p45ZGLaVou9SrJBCpfkzdyH0JSYUKyePHiMovJiRNOOCHLgtNlHMLFQCgugXsL2wWXgA8u
Qucy4+pvf/ub2WmnnTKVr1AhET169LCtHqFuNFmc+rvPEJLiFpJgjLgaXuVjmlZIvQoucJiryRu5
DyGpcCHRMtjaVpabfrp162a7AXIREhcDobgEroXwtL9mTBUqJDKSUuXzFtZLQ0jk1aBuNvVZq8UT
bDkhJFVLSJLitRDTtELqVdhKuS4mb4CQVJqQyKtZg+/qK/ajJbTPO++8nITExUAoKYGrr1iDnx7q
D1Z3V65C0rVrVztQnm/XVphhj7od9L3o+rSMuCo3QlJ1hSQpXgsxTSukXsUtuR5noAYISaUJibjg
ggusOY48M1QBNNNE+8tqMxchEUlGPC6D7eoj7tevn73jV/+wZqv4vbLDylAFnT59eqbloAH7OMOu
pL/DDHuEBvL13chjpKrGAELiFq+FmqblW6+CQuJq8gYISaUKiSrPmWeeae+gdPevQNYSIi4VMaxV
EmfEk5TAddcncyoJiFoF//znP21F16ypuDI0SKo+bk2zrFGjhp2q6/duyFVIwgx7hJKMvtvgNFCE
pGoKSVK8FmKalm+9CgpJLiZvgJBUehLRrCdXw54k0jAQErp783cvhKHZNLrjE19//XWkE1w+BA17
NPCqRKIkgZBUn2uOi9dCTNPSqle5mLyR+xCSkk8imuWigU3ddT3wwAN2Ro1mq6QhbmmgsZdzzjmH
GOCaASGhQhUrehhMM2UkIBrsVp/w2rVri+Lcvv/+eysk8+bNIwa4ZkBIqFBADHDNgJAAFQqIAa4Z
EBIqFBADXDMgJFQoIAa4ZkBIqFBADHDNgJAAFQqIAeIeEBIqFBADXDMgJFQoIAa4ZkBIqFBADHDN
gJAAFQoQEkBI+DqoUEAMcM2AkFChgBjgmgEhoVIBvz3XDlXztycSqFTAb853AAX95kRByl8wr9J5
AXFP3CMkwF0pAKSRA/gKACEBAIQEEBIAQEgAIQEAhAQQEgBASAAQEgBASAAhAQCEBBASAEBIACEB
AIQEACEBAIQEEBIAQEgAIQEAhAQQEgBASAAQEgBASAAhAQCEBBASAEBIACEBAIQEACEBAIQEEBIA
QEgAIQEAhAQQEgBASAAhAQCEBAAhAQCEBBASAEBIACEBAIQEEBIAQEgAEBIAQEgAIQEAhAQQEgBA
SAAhAQCEBAAhAQCEBBASAEBIoOgEJPgCAIQEACEBAIQEKkdMAAAhAUBIAAAhAYQEABASQEgAACGB
UhMTAEBIABASAEBIiiGh8iqdFwAgJNyVA785AEJCQgF+ewCEhEQCxAAAQkISAWIAACEBkggQAwAI
CUkEiAEAhIQkUkRce+21ZsaMGfzICAkAQlIZSeTUU081O++8s/nPf/6T9f77779v99m4cWPRX9ve
e+9tbr311szfZ599tr0uQEgAEJIKEhJ91q9fvwoVkhdeeMGMHj26XITkscceMw899BA/OkICgJBU
lJBss802ZssttzTvvvtuhQnJhRdeaNq3b18uQgIICQBCUsFCotZI3bp1zdFHH21+//33UCH57bff
zM0332wOPPBAU7t2bdOuXbss4QljxYoVpnfv3ma33XYze+yxh5kwYYJ9/+6777bdadtvv7055JBD
zGWXXWbf79u3r7nuuusy++uY+nz69OlZ71111VWmfv36Zr/99jNjxowpIyRXXnmlufTSS7P2ueaa
a8yee+5pz+PGG290Ok+EBAAhAUchUWJ++OGH7TYPPPBAqJBcf/31NvnffvvtZv78+XYcYttttzXL
ly+PPObAgQNN586dzdKlS83cuXPNggUL7Pva55RTTjHNmzc3s2fPNh999JF9v0OHDqZPnz5ZAqBz
eOqppzLv6Tx23XVXM378eLuftt9iiy1ix0g0GH/QQQeZ1157zZa14447mmeffTbxPBESAIQEchAS
oa6mevXqme+++y5LSDZt2mRbD4MGDcrst3nzZpuQlYSjaNOmjenVq5cVhCBhXVtJQvLLL7+YOnXq
mCuuuCJrP7VIbrnlllAh+fnnn+25qxXkcfLJJ5uzzjrL6TwREgCEBHIQkk8++cSOl0gw/EKyePHi
Mi0DccIJJ5hjjz028pjPPPOMbbW0aNHCtgYKFZJly5bZv5988skyQhLVItE1aZ8jjjjCHH/88fal
7Y855hin80RIABASyEFIhMYSttpqq0xXl4Tkgw8+sP9/8cUXs/bt1q2bHVeJY+HCheakk06y3U8j
R44sSEgWLVpk/3711VedheTDDz+0+6hLTILhvV555RWn80RIABASyFFIJBwNGza0A9OekGzYsMHO
6tJYgx8N0J933nlOxx86dKjZZZddMt1H/fv3N61bt87aplOnTqZnz56Zv2fNmpUlJJoIoAFxv2io
6yr4XrBrS62sSy65JK/zREgAEBLIUUiEWh6eKZI32H7BBReYxo0bmzlz5lhh0Qwuff7WW29FHnPS
pEl2RpSS8uDBg03btm2zPttuu+3M6tWrM+8NHz7cipi6sNRqaNq0aZkuNY1t6DzUKtGgv1oRtWrV
ihwjEVdffbWdKPD444+bn376yY4B+WecxZ0nQgKAkEAeQiJOP/30LCFR8j3zzDNty0SJW3ftDz74
YOwxNYitbjINkLds2dKKkMe6detMq1atbGvhoosusu8tWbLEHHroofa4TZo0MR9//HEZIVH3lqb9
6n21RKZOnZr4ZLtaJZdffrkdB9HAuwRM27icJ0ICgJBAyknkxx9/NCtXrsw8b5KEWgBr1qyJ/PzL
L7+02/j56quvEsv94osvcu5++vXXX83nn39u/831PIkBAISEL5AkQgwQA4CQAEkEiAEAhIQkAsQA
AEJCEgFiAAAhIYmUG5rJNXHixILLScOsCsMrhAQAIamAJJK2CVRa5aWxNHxSGaVmgIWQAEIC5ZJE
0jaBqkpCUmoGWAgJICRQJZJIVRISYgAAIYEUkkjQBMr7+4033rBPfO+zzz5Zy48IPQh4xx132CVM
9JR4o0aN7JImYUKSlllVkjmVSxlpXDtCAoCQICQJLQj9LRfEZs2amXHjxpkbbrjB7qsnwj0kDDVq
1DCjRo2yy5poQNszpwqWl5ZZVZI5lUsZaVw7QgKAkCAkDslU62h9+umn9m+ZSW299dbmvvvus39r
3Sq1Qjp27OhUXhpmVUnmVK6GV4VeO0ICgJAgJI7JNDjGoeSqO3ThGUWpaysNIXExq0oyp3I1vCr0
2hESAIQEIUkhmXpGUVHPiuQqJC5mVUnmVK6GVwgJ1QgQEigCIdEquVr6/ZRTTnEqLw2zqiRzKlfD
K4SEagQICRSBkIghQ4aYmjVr2sHuzZs32xaD7HjD9k/LrCrJnMqlDISEagQICRSJkCiRy3NdZlB6
aQaVZkuF7Z+WWVWSOZVLGQgJ1QgQEiiyJCJBcTW5SsusKs6cyrUMYgAAIQGSCBADAAgJSQSIAQCE
hCQCxAAAQkISAWIAACGBKpFE0jK8AoQEACEp0STiMtW2PI4DCAkAQlJNhSRoKvXCCy+Y0aNH51Rm
2D6lZlaFkAAgJCUrJEH0gGP79u1zKjOffYgBAIQEUk4iYYZQWmhx0qRJmW1czKmmTJliunfvbk2n
WrRokXnSPUpI/KZSWh5ey5/oiXWVe9lllyWWGbWPv9x+/frZJVr8aFmVI4880mzcuDHRLAshAUBI
wCGJuBhCuZhTKbFrKRF5eYwYMcIuZbJ+/fpIIfH/vXz5crsIZPPmzc3s2bMzJllxZUbt4y93woQJ
drkU/1PwAwYMMGeccYb9f5JZFkICgJBAQhJxNYRyERI/Svb6fNq0aU5CIpK6qcLKDNvHX+7atWut
MZW3j9brUitGfyeZZSEkAAgJOCQRV0MoVyFRy0AtByV4fT558uSChSSuzCQhEV26dDG9evWy/9f5
qgtLKxYnmWUhJAAICTgkEVdDqCQh0aKNStaNGjWyLRkZThUqJC5lugiJlp1Xy2PDhg1WVLzWV5JZ
FkICgJCAQxJxNYRKMqfS+IT+njlzpv1bXWa5Ckn//v1N69atM3+7lBncJ6xcCYiE5M4777RL3ntj
KUlmWQgJAEICjknExRAqyZxKy7prgF6D26tWrbImVPpcM8BchUSzxOQxsnr1aucyg/uElSvUstFA
fcuWLbPeTzLLQkgAEBJwSCIuhlAu5lSafqtkLefEYcOGmYsuusgmea+rKElI1q1bZ1q1amVbCdrX
pcywfcKERIPrOt+xY8dmvZ9kloWQACAkkEMS8RtCRTkLJplT6Y5ed/YeaknkypdffplVhkuZwX1y
JcksCyEBQEggxySSZFELCAkAQkISieX888+3YyGAkAAgJEASAWIAACEhiQAxAICQkEQyYHBFDAAg
JCSRgihv4ymMrRASAISkGiWRMOOp8k70GFshJAAISTVKIi5rYQFCAoCQVPEksmLFCtO7d2/7VLtW
xtWSJEKLNHpPi3toxdzDDjvMfPPNNxkDqTfeeMO0adPG7LPPPlnLqkQZT3lCErWfSDKcijpn4Te2
StqWGABASCCFJDJw4EDTuXNns3TpUjN37lyzYMEC+/69995rlx6RaHgMGTLEnHjiiRlBOPDAA02z
Zs2s+dQNN9xgj6EnxEWc8VTcfiLJcCrqnMNaPHHbEgMACAmkkETUKtCiht7yKB4SEK1B5c2w0uq7
9erVy3iXKGHvsssu1r3Q+1wmUvfdd1+mjKiurbj9XAynos45TEjitiUGABASSCGJ6Al2CYY80dUC
8NOjRw/Trl07+38t5ihL3k2bNoUmbCGBUCsjSUji9nMxnIo752D5cdsSAwAICaSURBYuXGiXj9ey
7SNHjsy8//zzz9v3NM6gbqpBgwY5C0K+QuJqOBV1zmHlR21LDAAgJJByEhk6dKhN6l43kLqd6tat
a82fZAqlhJyLkLgYTwX3y9VwKnjOcbPCgtsSAwAICaSQRGQOpRaHkuvgwYNN27Ztsz7XbCvtGzSF
chESV+Op4H5JhlNx5xxmmBV3fcQAAEICBSYRDUartVGnTh0rFnPmzMn6XAlc+44fPz5nIXE1ngru
l2Q4FXfOYYPtcddHDAAgJJBCEtFd/5o1a0I/09RdJXK1CvIlX+OpOMOpuHMuZFuEBAAhgZSTSNeu
Xc0555zDF4iQACAkJJHcv8Lvv//eCsm8efP4AhESAISEJMJXSAwQA4CQAEkEiAEAhIQkAsQAAEJC
EgFiAAAhIYkAMQCAkABJBIgBAISEJALEAABCQhIBYgAAISGJADEAgJAASQSIAQCEhCQCxAAAQkIS
AWIAACEhkQC/PQBCAiQU4DcHQEjKN7HwKp0XACAkwJ05ACAkgJAAAEICCAkAICSAkAAAQgKAkAAA
QgIICQAgJICQAABCAggJACAkAAgJACAkgJAAAEICCAkAICSAkAAAQgKAkAAAQgIICQAgJICQAABC
AggJACAkAAgJACAkgJAAAEICCAkAICSAkAAAQgKAkAAgJAAICQAgJICQAABCAggJACAkgJAAAEIC
gJAAAEICCAkAICSAkAAAQgIICQAgJAAICQAgJICQAABCAggJACAkUC0FJPgCAIQEACEBAIQEKkdM
AAAhAUBIAAAhAYQEABASQEgAACGBUhMTAEBIABASAEBIiiGh8iqdFwAgJNyVA785AEJCQgF+ewCE
hEQCxAAAQkISAWIAACEBkggQAwAICUkEiAEAhIQkUgFce+21ZsaMGRV6zMWLF5tNmzblte8vv/xi
1q5d67TtsmXLzDXXXGPOOOMMM2XKFKd9HnzwQTNx4sTIvxESAISk0oVk5cqVpnbt2uaqq64qinPe
e++9za233pr5++yzzzannnpquR1v4cKF5vDDDzebN2+2f3/++edlnsnYYostyuw3atQo06FDB1Or
Vi0zcuTIxOOo/J133tnccccdZvbs2ebtt992Or/g9ef6fSAkgJBAuQvJSSedZLcrREheeOEFM3r0
6HIRkscee8w89NBD5fYdtW7d2owbNy7ztyckjzzyiHn66aft65lnnimzX48ePcztt99udt99dych
mTt3rtlyyy3Nxo0bczo/hAQAISlqIVGC3nPPPc3JJ59srr766ryPc+GFF5r27duXi5CUJ88//7zZ
d999s7q1PCH5/vvvncpo2LChk5CoO2r77bfP+RwREgCEpGiF5Msvv7RdLdOmTTPnnntuopCsWLHC
9O7d2+y2225mjz32MBMmTLDv33333bYcJclDDjnEXHbZZfb9vn37muuuuy6z/2+//WY/nz59etZ7
agnVr1/f7LfffmbMmDFlhOTKK680l156adY+GmeQAOo8brzxRqfzjErSgwcPznqvPITEE2y1SPQd
aIzE9TtCSAAQkqIVkq5du5oLLrjA/t9FSAYOHGg6d+5sli5dartpFixYYN9fvny5OeWUU0zz5s1t
3/9HH31k39f4QZ8+fbKSpM7nqaeeyrx3/fXXm1133dWMHz/e7qftNR4RN0aiwfiDDjrIvPbaa7as
HXfc0Tz77LOJ5xmGxoaCXXKekEi87r33XvPdd98VLCRffPGFueKKK8x2221nv6P33nvP+TtCSAAQ
kqIUkieeeMJ26Xh33S5C0qZNG9OrVy+b7IKEdW0lJUnNdqpTp45NsH7UIrnllltCE+fPP/9sWz5q
BXmoW+6ss85yOk8/3377rT0fdW/5+eabb6xYdenSxYqUhE6ClEbX1g477JDTd4SQACAkRSkkX3/9
te320Z34xx9/bF9/+tOfbEJbsmRJZFkacN52221NixYtbGugUCHRVFj9/eSTT5YRkqgWySeffGL3
OeKII8zxxx9vX9r+mGOOcTpPP2pJqax58+ZFbvPrr7+agw8+2DRq1AghAUBIEBKPl156KXLpcSXl
ODRVVrO81P3kT575CMmiRYvs36+++qqzkHz44Yd2H3WJSTC81yuvvOJ0nn5+/PFHW5ZmZcUxduxY
u92///1vhAQAIUFIoujUqVNOs7aGDh1qdtlll0z3Uf/+/e002mCZPXv2zPw9a9asrCT5+++/25aR
XzTUdRV8L9i1tc0225hLLrkkr/MMItG67bbbYsvQcx8679WrV6cuJEnfEUICgJBUKyGZNGmSnRGl
pKyZTm3bts36TAPJ/mQ7fPhwm2TVhaVWQ9OmTcskSY1tNG7c2LZK5s+fb1sResAvaoxE6Dw1S+zx
xx83P/30kx0Mf/fdd53OM8igQYOyWgTihx9+sK0Voe6vww47zHaTBdHzINquQYMGtoWk/2vcJxch
cfmOEBIAhKTaCIkGsbfaais7QN6yZUszZ86czGfr1q0zrVq1sq2Fiy66yL6n8ZZDDz3UnkOTJk3s
WEwwSap7S9N+9b5aIlOnTk18sl2tkssvv9yOg2jgXQKmbVzOM4jOUVOEJRgeerhS+2tmmLrGNP7y
2Wefldl3r732KtM16J/K6yIkLt8RQgKAkFQJIXFFLYA1a9ZEfq5nU7SNn6+++iqxXE2PTZplFUQD
4Zqqq39zPU8/Wtfr9NNPzypXLQQNwuu8KgKX76hYYgAAIUFIIKK1sGHDBmIAACEBkggQAwAICUkE
iAEAhIQkAsQAAEJCEql25GoIFYVmmuU6MYAYAEBIEJIiJZepsGkZZMkfxT/dmBgAQEhKUkjSNKKq
iHKjys7F9CotIZHT4YEHHpi4tApCAoCQVGshSdOIqiLKTaPsNC17H330UftEPkICgJCUpJBEGVHF
GUZpaXWtpXXTTTdl3ZnLh0RjD3HlBpkyZYrp3r27PYaWHpEXiR/PyEpL3Wvl3bvuuiuy7DDTK62N
paVG9MS7Vu31bHKDQlKIQZaWQqlRo4Zd1gUhAUBISk5IooyokgyjdBcuhz/tI5Swlei1ZElcuWFC
Jo/0Tz/91IwYMcIudbJ+/fqslsP+++9vjj76aOubrmVEosoOioOWKFGCHzVqlN1PT61HbVuoQZbW
2LrhhhsQEgCEpPSEJKybyMUwSsgAa5999rGLJGrdqDfffDO23CQkIDpH2f36hUSthOCyIWFlB1cG
ViukY8eOocdK2yBL5/LnP/8ZIQFASBAS4WIY5SV+dRdpccaLL744sdwo1KpQa0Tb67iTJ08OTfi5
CIl3DWopJQlJGgZZPXr0MN26dUNIABAShES4GkbJnlYtEq2KK8OnXIVEHiS6y5cYaal4lZ+WkHjX
EPWsSNoGWRIdb6VjhAQAISk5IQkaUbkaRkkE5GUuEVA3kpY9jys3iMYrdE4zZ860f2vQ2lVIwsr2
b6sVf3UNGktJEpI0DLJ23313c+eddyIkAAhJaQpJmBFVkmGUZlHVrVvXLs+uloXGIuSl4V82Pqxc
P1r2XXf3mgG1atUqe0yd45gxYxKFJKzs4LZDhgwxNWvWtIPmmlWmlscHH3wQum0hBlnaVtfxr3/9
CyEBQEhKU0jCjKjiDKPky6Gk+9xzz2XKUEKXsAwYMCC23CCauqtjKOEPGzbMbqdjed1KUUISVnZw
WwmCusBkTKWXZmJ504vTNMjStONzzjmnSscAAEICqSSRMCOqOMMoV8LK9aM7ev/nap2kVbYnKCtX
rrQtpyRyNcjSQP1xxx2XeA4ICQBCUhJCArnz97//3Xz99dfEAABCgpAAMQCAkABJBIgBAISEJALE
AABCQhJJzTRK619pfazKLoMYAEBIICGJpLmkeprlaZmSW2+9tVzLSPvaERIAhKQkk0guhlDVTUjS
vnaEBAAhIYmUmJAQAwAICaSQRIKGUN7fb7zxhn2iWwszaj0tP7mYRvXt29d6g/j3lSHV9OnTs967
6qqrTP369c1+++1nl0kJikCS+ZRLGWlcO0ICgJAgJAktCP0tH/JmzZpZ0ykZNmlfPfHtkYtpVIcO
HUyfPn2yEr7Kk4GUh1be3XXXXe0SJipH22v9Kr8IJJlPuZSRxrUjJAAICULikEy1uq1cC4VW5d16
663NfffdZ//OxTTKRUhUvtawuuKKK7LKUWvCaw0kmU+5lJHGtSMkAAgJQuKYTINjHEquukMXuZhG
uQjJsmXL7N9PPvlkGRHwWhNJ5lMuZaRx7QgJAEKCkKSQTHMxjXIRkkWLFtm/X3311UgRSDKfcikD
IUFIAKgBRSIkuZhGiU6dOpmePXtm/p41a1aWkGhV3t122y0r4asry/9ekvmUSxkICUICQA0oEiER
uZhGDR8+3DRs2NB2P6kVoZlewcF2jXU0btzYtijmz59vLW1r1aqVNb6RZD7lUgZCQjUChASKREhy
MY3SrC65J+r4TZo0sZa8QSFR15Sm7Op9tSKmTp1aplsqyXzKpQyEhGoECAkUWRLJxTTqq6++StxG
7ot+L/Qwksy2XMogBgAQEiCJADEAgJCQRIAYAEBISCJADAAgJCQRIAYAEBIgiQAxAICQkESiKC/z
qVIztUJIABCSkkgiL7zwghk9enTWe0HzqbBt0iiXGABASKAaJBE95Ni+ffuCt0ljH2IAACEBxyQS
ZgilhRYnTZqU2cbFnGrKlCmme/fu1nSqRYsWmSfdPZJMo7REvJZA0VPrKvuyyy7L2i9um7hju5Tb
r18/u5SLHy2/cuSRR5qNGzcmmmohJAAISUkLiYshlIs5lRK2lhKRl8eIESPsUibr16/PfJ5kGrV8
+XK7EGTz5s3N7NmzQ42yoraJO7ZLuRMmTLDLqviflh8wYIA544wz7P+TTLUQEgCEpGSFxNUQykVI
/CiJ6/Np06ZlCUmSaVRYF1RwUDypmyrs2Enlrl271p6Lt4/W9VIrRn8nmWohJAAISUkLiashlKuQ
6I5fLQIlbn0+efLkSEEQwQURCxGSuGO7lNulSxfTq1cv+39dl7qwtLJxkqkWQgKAkJS0kLgaQiUJ
iRZtVBJu1KiRbcnIcKqihMTl2C7lanl6tTw2bNhgRcVrpSWZaiEkAAhJSQuJqyFUkjmVxh3098yZ
M+3f6rbKR0j69+9vWrduHZvwg9u4HNulXAmIhOTOO++0S+N7YylJploICQBCUtJCIlwMoZLMqTRg
rgF6DVqvWrXKmlDpc80Ay0VINFNMPiOrV6+O3C+4jcuxXcoVatlooL5ly5ZZ7yeZaiEkAAhJSQuJ
iyGUizmVptUqCcs5cdiwYeaiiy6yydvrAnIRknXr1plWrVrZFoD2D9svbJukY7uUKzS4rusaO3Zs
1vtJploICQBCUtJC4uE3hIpyFkwyp9Kduu7YPdRCyIcvv/wyqxyXbVyO7VJuHEmmWggJAEJS0kLi
J8miFqp/DAAgJFBQEjn//PPtWAggJAAICZBEgBgAQEhIIkAMACAkJJEMDz74oJk4cSI/CEICgJCQ
RPKjvA2lStGwCiEBQEiqbRIJM5Qq70RfioZVCAkAQlJtk4jLGleAkAAgJFU8iaxYscL07t3bPtWu
FW+11IjQIo3eU+AeWgn3sMMOM998803eRlWekETtJ5KMpKLOWfgNq5K2JQYAEBJIIYkMHDjQdO7c
2SxdutTMnTvXLFiwwL5/77332iVFJBoeQ4YMMSeeeGJGEPI1qorbTyQZSUWdc1iLJ25bYgAAIYEU
kohaBVqs0FsexUMCorWlvBlWWlW3Xr16Ge+SQoyq4vZzMZKKOucwIYnblhgAQEgghSSiJ9glGPI6
VwvAT48ePUy7du3s/7WYoyx5N23aFJqwRT7+IsH9XIyk4s45WH7ctsQAAEICKSWRhQsX2uXjtRz7
yJEjM+8///zz9j2NM6ibatCgQc6CkK+QuBpJRZ1zWPlR2xIDAAgJpJxEhg4dapO61w2kbqe6deta
UyeZPSkh5yIkLoZSwf1yNZIKnnPcrLDgtsQAAEICKSQRmT6pxaHkOnjwYNO2bduszzXbSvsGzZ7S
MqoK2y/JSCrunMOMsOKujxgAQEigwCSiwWi1NurUqWPFYs6cOVmfK4Fr3/Hjx+csJK6GUsH9koyk
4s45bLA97vqIAQCEBFJIIrrrX7NmTehnmrqrRK5WQb7kaygVZyQVd86FbIuQACAkkHIS6dq1qznn
nHP4AhESAISEJJL7V/j9999bIZk3bx5fIEICgJCQRPgKiQFiABASIIkAMQCAkBRrElm8eHHmqXX4
f1S0EdeiRYvK7TkXhAQQEii3JKIHDQ8//HCzefNmvqgAaS1771qO/FT8U50REgCEpEoIiZ4+9z/H
UR6EmVyVkpC4Gm5JzLU68tNPP42QACAkVUNItJ7WvvvuW+7dWmHrbpWSkOTCo48+aho3boyQACAk
VUNIlCi1dIgfzxxKCyUeddRRZq+99jJjxoyxDwbK30PLyXfp0sV6fHjEmVFFmVxNmTLFdO/e3W6v
1XmDT88nkbR/kvmWSxl+IUky+0rLcEtrnNWoUcPMnz8fIQFASIpfSGrXrh3qq6474j/+8Y/WWMpb
tPFPf/qTGTBggO2matiwoTW68ogzo4oyuZLAqEtN3iQjRoywS6KsX7/e+ZqS9ncx0XIpwxOSJLOv
NA23GjRoYM8XIQFASIpaSL799lv7vrq3gkKiROYtK7Js2TK73V//+tesRCihES5mVEldW0reOsa0
adPyur6w/V3Mt1zK8AQgyewrTcMtfVd//vOfERIAhKS4hUQtBb0ffHI9mPS0Vpa2e/3117PuxNUV
5HXvJJlRRQmJWihqCehzlTF58uTMZ9pfXWvBlwTQZX+XBSJzLSPO7CtNwy0dp1u3bggJAEJS3ELy
448/2veDM4RyFRIXM6qgkPz+++/2jrxRo0Z23ELbBpP4yy+/bF566aUyL7UEXPZPEpJ8yogz+xJp
GW5JRIPjMQgJAEJSdEIi1HK47bbbChISFzOqoMmVxklU5syZMzPdRMEkHofL/klCkk8ZcWZffgo1
3Np9993NnXfeiZAAICTFLyS6o9ZspEKERLiYUflNrjTgrTtxzVZatWqV3V/H0OwwF1z2TxKSfMuI
MvtKy3BL353O61//+hdCAoCQFL+QLFmyxE4/1XhJIUKSZEYVZnKlhKzta9asaYYNG2bf135Bf/Yo
kvZ3GSPJp4wos6+0DLc0Vbg8lu5HSAAhgXJLIjNmzDCnn356KseJM6PyRMlvcqW7b//fahnkQqH7
51NGnNlXoYZbmrhw3HHH5WUEhpAAICSVJiRCU1o3bNjAF+VAeZp9/f3vfzdff/11pcQAAEICJJEK
oCqbfREDgJAASQSIAQCEhCQCxAAAQkISAWIAACEhiQAxAICQAEkEiAEAhIQkAsQAAEJCEgFiAAAh
IYkAMQCAkABJBIgBAISEJALEAABCQhIBYgAAISGJADEAgJAAiQT47QEQEhIK8JsDICRFnVh4lc4L
AP4v/x+udxkTLLh+pgAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-07-09 22:11:27 -0700" MODIFIED_BY="James M Wright" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAOgAAAG1CAIAAAB8rC+yAAAMpklEQVR42u3dz4scZR7H8ceLe5nD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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2014-05-31 06:52:44 -0700" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2012-10-17 18:38:34 -0700" MODIFIED_BY="Ciprian D Jauca" NO="1">
<TITLE MODIFIED="2012-10-17 18:27:16 -0700" MODIFIED_BY="Ciprian D Jauca">Should mild hypertension be treated? The possible benefits of angiotensin receptor blockers</TITLE>
<DATE_SUBMITTED>
<DATE DAY="12" MONTH="9" YEAR="2012"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2012-10-17 18:34:49 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>We read with interest the manuscript of Diao D et al at about the possible benefits of treating mild hypertensive patients in primary prevention. (Diao 2012) In this study, 4 randomized clinical trials, with a total of 8,912 patients, were included for the analysis. After a follow-up of 4-5 years, antihypertensive treatment was not followed with a reduction of total mortality, coronary heart disease, stroke or total cardiovascular events. Even more, antihypertensive treatment was associated with an increased risk of withdrawals due to adverse effects.</P>
<P>Although the implications of this study are of great interest, the fact is it has important limitations that hamper its conclusions to be translated into clinical practice. Firstly, the relative small sample size, with less than 9,000 patients included. Indeed, not many studies have analyzed this population. By contrast, current outstanding clinical trials actually include a greater population to allow attaining clinically relevant conclusions (i.e. in LIFE, 9,193 patients were included (Dahlöf 2002), in ACCOMPLISH, 11,506 patients (Jamerson 2008). This is even more important taking into account that in these studies high risk hypertensive patients were included, with more expected outcomes. As cardiovascular risk lowers, more patients are required to really ascertain whether a treatment is effective or not.</P>
<P>Moreover, follow up was limited to 4 to 5 years in the included studies. However, in general, hypertension-related organ damage needs time to establish and more time to develop cardiovascular complications. Moreover, this time is even longer in mild hypertension. Thus, to actually establish the real benefits of antihypertensive therapy in this population, longer follow-up is warranted or at least, intermediate endpoints, such as left ventricular hypertrophy or microalbuminuria, should be analyzed (Mancia 2009).</P>
<P>Finally, it is also important to analyze the antihypertensive therapy used in the studies included in this meta-analysis (ANBP: chlorothiazide, methyldopa, propranolol, or pindolol added as 2nd-order treatment, and hydralazine or clonidine added as 3rd-order treatment; control placebo; MRC: bendrofluazide, propranolol, methyldopa added if required; control placebo; SHEP: chlorthalidone, step 2 atenolol or reserpine; identical placebo; VA-NHLBI: chlortalidone, reserpine; control placebo) (Diao D 2012). Many of these drugs are not currently being used. In fact, modern antihypertensive agents are more effective or better tolerated than those used in most of these studies.</P>
<P>On the other hand, beta blockers (present in all the analyzed studies) are commonly withdrawn due to side effects in a significant proportion of patients. This fact occurs even in secondary prevention (Gislason 2006). Medication adherence is important to assure the benefits of therapy during follow-up. In fact, when the efficacy of 2 drugs is similar, the agent with lesser rates of side effects should be chosen. For example, in the ONTARGET trial, although telmisartan and ramipril similarly reduced cardiovascular outcomes, when discontinuation of study medication was included in the analysis, a trend to lesser outcomes was observed with telmisartan (Barrios 2008). If using drugs with lower side effects is important in secondary prevention, this is even more relevant in primary prevention where patients do not have symptoms. With regard to first-line current antihypertensive drugs (diuretics, beta blockers, calcium channel blockers, angiotensin converting enzyme inhibitors and angiotensin receptor blockers), it seems that angiotensin receptor blockers could be the better tolerated agents.</P>
<P>Although specific and appropriate clinical trials are needed to ascertain the benefits of antihypertensive therapy in patients with mild hypertension, it should be currently recommended to reduce blood pressure values to established targets in patients with mild hypertension, but with those drugs better tolerated.</P>
<P>References</P>
<OL>
<LI>Barrios V, Escobar C, Prieto L, Herranz I. Adverse events in clinical trials: is a new approach needed? Lancet. 2008;372(9638):535-6.</LI>
<LI>Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995&#8211;1003.</LI>
<LI>Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev. 2012;8:CD006742.</LI>
<LI>Gislason GH, Rasmussen JN, Abildstrøm SZ, Gadsbøll N, Buch P, Friberg J, Rasmussen S, Køber L, Stender S, Madsen M, Torp-Pedersen C. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27(10):1153-8.</LI>
<LI>Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28.</LI>
<LI>Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121-58.</LI>
</OL>
<P>We agree with the conflict of interest statement below:<BR/>
<BR/>We certify that we have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of our feedback.<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2012-10-17 18:38:34 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>We thank Drs. Barrios and Escobar for their comments.</P>
<P>Regarding the number of RCT participants included in this systematic review (n=8,912), we agree that it would be good if there were more data, however, this review does represent all the participants and data that are available at this time. Thus at the present time we do not have proof that the benefits of drug treatment outweigh the harms for primary prevention patients with mild elevations in blood pressure, a group that represents half of the hypertensive population. </P>
<P>We agree with Barrios and Escobar's conclusions that "specific and appropriate clinical trials are needed to ascertain the benefits of antihypertensive therapy in patients with mild hypertension". However, we disagree with their conclusions that "it should be currently recommended to reduce blood pressure values to established targets in patients with mild hypertension, but with those drugs better tolerated". Widespread treatment in the absence of evidence is never a good approach. Patients who are offered drug treatment need to be told that drug treatment has not been proven to be beneficial.<BR/>
</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-10-17 18:29:21 -0700" MODIFIED_BY="Ciprian D Jauca">
<P>Vivencio Barrios &lt;vbarriosa@medynet.com&gt; and Carlos Escobar<BR/>Affiliation: Hospital Ramon y Cajal, Madrid, Spain and Hospital La Paz, Madrid, Spain<BR/>Role: Cardiologists</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2014-05-31 06:52:44 -0700" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-11-15 14:43:27 -0800" MODIFIED_BY="Ciprian D Jauca">The results of this review should be interpreted (appropriately) as subgroup analyses</TITLE>
<DATE_SUBMITTED>
<DATE DAY="15" MONTH="11" YEAR="2013"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-11-15 14:45:37 -0800" MODIFIED_BY="Ciprian D Jauca">
<P>The review authors have addressed an important question: Do the benefits of antihypertensive drugs outweigh the downsides for healthy individuals with mild hypertension? To answer this question, the authors have conducted subgroup analyses. Their implicit question is whether the relative effects for mild hypertension are different from the relative effects for moderate and severe hypertension. However, they do not present or interpret their findings as subgroup analyses &#8211; we think they should. They also do not provide a biological rationale or indirect evidence to support an assumption that the relative effects are different.<BR/>
<BR/>For example, only one trial in the review contributed data on strokes as an outcome. The effect estimate in that trial was a 50% relative risk reduction (RR 0.51) with a 95% confidence interval that included no effect (95% CI 0.24 to 1.08). The review authors interpret this as meaning &#8220;treatment with antihypertensive drugs as compared to placebo did not reduce&#8221; stroke. We disagree with this interpretation, which in our view confuses inconclusive evidence (from this subgroup analysis) with evidence of no effect (1).<BR/>
<BR/>Given overlapping confidence intervals for the subgroup effects and the overall effects across people with different degrees of hypertension (a high likelihood that chance explains any apparent subgroup differences), and taking into consideration other criteria for assessing the credibility of subgroup effects (2), a reasonable conclusion is that the relative effectiveness of blood pressure lowering medication is likely the same across patients with different degrees of hypertension. Indirect evidence from observational studies of hypertension as a risk factor for cardiovascular disease also support this interpretation, since the risk seems to be proportional with the level of blood pressure, with no clear lower threshold (3).<BR/>
<BR/>The absolute effects on cardiovascular outcomes, and therefore the net benefit from treating hypertension with medication is less for patients with mild hypertension than it is for patients with moderate or severe hypertension. On that basis there are good reasons to question the value of drug treatment for patients with mild hypertension. However, this is because of a lower baseline risk for cardiovascular events, not because of a smaller relative effect.<BR/>
<BR/>Our interpretation of the subgroup analyses presented in this review is that treatment decisions should be based on the overall estimate of the relative effect, not on the estimates from these subgroup analyses (4).<BR/>
<BR/>1.Results should not be reported as statistically significant or statistically non-significant. Oslo: Effective Practice and Organisation of Care (EPOC), Norwegian Knowledge Centre for the Health Services; 2013.<BR/>2.Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. Bmj. 2010;340:c117. PubMed PMID: 20354011.<BR/>3.MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990 Mar 31;335(8692):765-74. PubMed PMID: 1969518.<BR/>4.Oxman AD. Subgroup analyses. Bmj. 2012;344:e2022. PubMed PMID: 22422834.<BR/>
<BR/>
<BR/>We agree with the conflict of interest statement below:<BR/>
<BR/>We certify that we have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of our feedback.<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2014-05-31 06:52:44 -0700" MODIFIED_BY="[Empty name]">
<P>We thank Fretheim and Oxman for their comments on our review.</P>
<P>Historically, the benefit from drug treatment of hypertension has been demonstrated in predominantly moderate to severe hypertensive populations. Despite that recommendations have progressively extended the population to be treated from severe hypertension to moderate hypertension and then to mild hypertension (140-159/90-99 mmHg). Mild hypertension represents a very large group of people, approximately half of the people labeled as having hypertension. It is thus vitally important to look at the level of evidence within that sub-group. The conclusion of the review is that there is a lack of evidence in this sub-group, despite its numerical importance.</P>
<P>The interpretation proposed by Fretheim and Oxman is focused on the question whether there is evidence of differences between relative risk in mild hypertension compared to moderate to severe hypertension, i.e. the usual way to look at sub-group analyses. They limit their comments to the case of stroke, which we agree does not suggest evidence for a difference. However, other outcomes such as MI or total cardiovascular disease events display different results with average effect estimates in mild hypertension outside of the CI of the average effects in more severe hypertension.</P>
<P>We agree with the conclusion of Fretheim and Oxman: "The absolute effects on cardiovascular outcomes, and therefore the net benefit from treating hypertension with medication is less for patients with mild hypertension than it is for patients with moderate or severe hypertension. On that basis there are good reasons to question the value of drug treatment for patients with mild hypertension." We would change the rationale for that statement to: &#8220;This is because of a lower baseline risk for cardiovascular events, and also because of important uncertainties regarding the specific relative effect of treatment in this subgroup.&#8221;</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-11-15 14:44:52 -0800" MODIFIED_BY="Ciprian D Jauca">
<P>Name: Atle Fretheim and Andrew D. Oxman<BR/>Email Address: atle.fretheim@nokc.no<BR/>Affiliation: Global Health Unit, Norwegian Knowledge Centre for the Health Services</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2014-04-07 13:33:17 -0700" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-10-17 17:48:45 -0700" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-02-14 18:10:58 -0800" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-17 17:48:45 -0700" MODIFIED_BY="[Empty name]">
<P>Database: Ovid MEDLINE(R) 1946 to Present with Daily Update<BR/>Search Date: 16 October 2013<BR/>--------------------------------------------------------------------------------<BR/>1 exp thiazides/<BR/>2 exp sodium potassium chloride symporter inhibitors/<BR/>3 ((loop or ceiling) adj diuretic?).tw.<BR/>4 (amiloride or benzothiadiazine or bendroflumethiazide or bumetanide or chlorothiazide or cyclopenthiazide or furosemide or hydrochlorothiazide or hydroflumethiazide or methyclothiazide or metolazone or polythiazide or trichlormethiazide or veratide or thiazide?).tw.<BR/>5 (chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or oxodoline or thalitone or hygroton or indapamide or metindamide).tw.<BR/>6 or/1-5<BR/>7 exp angiotensin-converting enzyme inhibitors/<BR/>8 ((angiotensin$ or kininase ii or dipeptidyl$) adj3 (convert$ or enzyme or inhibit$ or recept$)).tw.<BR/>9 (ace adj3 inhibit$).tw.<BR/>10 acei.tw.<BR/>11 exp enalapril/<BR/>12 (alacepril or altiopril or benazepril or captopril or ceronapril or cilazapril or delapril or enalapril or fosinopril or idapril or imidapril or lisinopril or moexipril or moveltipril or pentopril or perindopril or quinapril or ramipril or spirapril or temocapril or trandolapril or zofenopril or aliskiren or enalkire or remikiren).tw.<BR/>13 or/7-12<BR/>14 exp Angiotensin II Type 1 Receptor Blockers/<BR/>15 exp losartan/<BR/>16 (KT3-671 or candesartan or eprosartan or irbesartan or losartan or olmesartan or tasosartan or telmisartan or valsartan).tw.<BR/>17 (angiotensin$ adj4 receptor$ adj3 (antagon$ or block$)).tw.<BR/>18 or/14-17<BR/>19 exp calcium channel blockers/<BR/>20 (calcium channel block$ or amlodipine or amrinone or bencyclane or bepridil or cinnarizine or conotoxins or diltiazem or felodipine or fendiline or flunarizine or gallopamil or isradipine or lidoflazine or magnesium sulfate or mibefradil or nicardipine or nifedipine or nimodipine or nisoldipine or nitrendipine or perhexiline or prenylamine or verapamil or omega-agatoxin iva or omega-conotoxin gvia or omega-conotoxins).tw.<BR/>21 (calcium adj2 (inhibit$ or antagonist? or block$)).tw.<BR/>22 or/19-21<BR/>23 (methyldopa or alphamethyldopa or amodopa or dopamet or dopegyt or dopegit or dopegite or emdopa or hyperpax or hyperpaxa or methylpropionic acid or dopergit or meldopa or methyldopate or medopa or medomet or sembrina or aldomet or aldometil or aldomin or hydopa or methyldihydroxyphenylalanine or methyl dopa or mulfasin or presinol or presolisin or sedometil or sembrina or taquinil or dihydroxyphenylalanine or methylphenylalanine or methylalanine or alpha methyl dopa).mp.<BR/>24 (reserpine or serpentina or rauwolfia or serpasil).mp.<BR/>25 (clonidine or adesipress or arkamin or caprysin or catapres$ or catasan or chlofazolin or chlophazolin or clinidine or clofelin$ or clofenil or clomidine or clondine or clonistada or clonnirit or clophelin$ or dichlorophenylaminoimidazoline or dixarit or duraclon or gemiton or haemiton or hemiton or imidazoline or isoglaucon or klofelin or klofenil or m-5041t or normopresan or paracefan or st-155 or st 155 or tesno timelets).mp.<BR/>26 exp hydralazine/<BR/>27 (hydralazin$ or hydrallazin$ or hydralizine or hydrazinophtalazine or hydrazinophthalazine or hydrazinophtalizine or dralzine or hydralacin or hydrolazine or hypophthalin or hypoftalin or hydrazinophthalazine or idralazina or 1-hydrazinophthalazine or apressin or nepresol or apressoline or apresoline or apresolin or alphapress or alazine or idralazina or lopress or plethorit or praeparat).tw.<BR/>28 or/23-27<BR/>29 exp adrenergic beta-antagonists/<BR/>30 adrenergic beta antagonist?.tw.<BR/>31 (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol).tw.<BR/>32 (beta adj2 (antagonist? or receptor? or adrenergic? block$)).tw.<BR/>33 or/29-32 [BBs]<BR/>34 exp adrenergic alpha antagonists/<BR/>35 (alfuzosin or bunazosin or doxazosin or metazosin or neldazosin or prazosin or silodosin or tamsulosin or terazosin or tiodazosin or trimazosin).tw.<BR/>36 (andrenergic adj2 (alpha or antagonist?)).tw.<BR/>37 ((andrenergic or alpha or receptor?) adj2 block$).tw.<BR/>38 or/34-37<BR/>39 hypertension/<BR/>40 hypertens$.tw.<BR/>41 ((high or elevat$ or rais$) adj2 blood pressure).tw.<BR/>42 or/39-41<BR/>43 randomized controlled trial.pt.<BR/>44 controlled clinical trial.pt.<BR/>45 randomized.ab.<BR/>46 placebo.ab.<BR/>47 dt.fs.<BR/>48 randomly.ab.<BR/>49 trial.ab.<BR/>50 groups.ab.<BR/>51 or/43-50<BR/>52 animals/ not (humans/ and animals/)<BR/>53 Pregnancy/ or Hypertension, Pregnancy-Induced/ or Pregnancy Complications, Cardiovascular/ or exp Ocular Hypertension/<BR/>54 (pregnancy-induced or ocular hypertens$ or preeclampsia or pre-eclampsia).ti.<BR/>55 51 not (52 or 53 or 54)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-10-17 17:48:48 -0700" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-02-14 18:11:18 -0800" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-17 17:48:48 -0700" MODIFIED_BY="[Empty name]">
<P>Database: Embase &lt;1974 to 2013 Week 41&gt;<BR/>Search Date: 16 October 2013<BR/>--------------------------------------------------------------------------------<BR/>1 exp thiazide diuretic agent/<BR/>2 exp loop diuretic agent/<BR/>3 ((loop or ceiling) adj diuretic?).tw.<BR/>4 (amiloride or benzothiadiazine or bendroflumethiazide or bumetanide or chlorothiazide or cyclopenthiazide or furosemide or hydrochlorothiazide or hydroflumethiazide or methyclothiazide or metolazone or polythiazide or trichlormethiazide or veratide or thiazide?).tw.<BR/>5 (chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or oxodoline or thalitone or hygroton or indapamide or metindamide).tw.<BR/>6 or/1-5<BR/>7 exp dipeptidyl carboxypeptidase inhibitor/<BR/>8 angiotensin converting enzyme inhibit$.tw.<BR/>9 (ace adj2 inhibit$).tw.<BR/>10 acei.tw.<BR/>11 (alacepril or altiopril or ancovenin or benazepril or captopril or ceranapril or ceronapril or cilazapril or deacetylalacepril or delapril or derapril or enalapril or epicaptopril or fasidotril or fosinopril or foroxymithine or gemopatrilat or idapril or imidapril or indolapril or libenzapril or lisinopril or moexipril or moveltipril or omapatrilat or pentopril$ or perindopril$ or pivopril or quinapril$ or ramipril$ or rentiapril or saralasin or s nitrosocaptopril or spirapril$ or temocapril$ or teprotide or trandolapril$ or utibapril$ or zabicipril$ or zofenopril$).tw.<BR/>12 or/7-11<BR/>13 exp angiotensin receptor antagonist/<BR/>14 (angiotensin adj3 (receptor antagon$ or recetor block$)).tw.<BR/>15 arb?.tw.<BR/>16 (abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan or forasartan or irbesartan or losartan or milfasartan or olmesartan or saprisartan or tasosartan or telmisartan or valsartan or zolasartan).tw.<BR/>17 or/13-16<BR/>18 calcium channel blocking agent/<BR/>19 (amlodipine or amrinone or aranidipine or barnidipine or bencyclane or benidipine or bepridil or cilnidipine or cinnarizine or clentiazem or darodipine or diltiazem or efonidipine or elgodipine or etafenone or fantofarone or felodipine or fendiline or flunarizine or gallopamil or isradipine or lacidipine or lercanidipine or lidoflazine or lomerizine or manidipine or mibefradil or nicardipine or nifedipine or niguldipine or nilvadipine or nimodipine or nisoldipine or nitrendipine or perhexiline or prenylamine or semotiadil or terodiline or tiapamil or verapamil).tw.<BR/>20 (calcium adj2 (antagonist? or block$ or inhibit$)).tw.<BR/>21 or/18-20<BR/>22 (methyldopa or alphamethyldopa or amodopa or dopamet or dopegyt or dopegit or dopegite or emdopa or hyperpax or hyperpaxa or methylpropionic acid or dopergit or meldopa or methyldopate or medopa or medomet or sembrina or aldomet or aldometil or aldomin or hydopa or methyldihydroxyphenylalanine or methyl dopa or mulfasin or presinol or presolisin or sedometil or sembrina or taquinil or dihydroxyphenylalanine or methylphenylalanine or methylalanine or alpha methyl dopa).mp.<BR/>23 (reserpine or serpentina or rauwolfia or serpasil).mp.<BR/>24 (clonidine or adesipress or arkamin or caprysin or catapres$ or catasan or chlofazolin or chlophazolin or clinidine or clofelin$ or clofenil or clomidine or clondine or clonistada or clonnirit or clophelin$ or dichlorophenylaminoimidazoline or dixarit or duraclon or gemiton or haemiton or hemiton or imidazoline or isoglaucon or klofelin or klofenil or m-5041t or normopresan or paracefan or st-155 or st 155 or tesno timelets).mp.<BR/>25 hydralazine/<BR/>26 (hydralazin$ or hydrallazin$ or hydralizine or hydrazinophtalazine or hydrazinophthalazine or hydrazinophtalizine or dralzine or hydralacin or hydrolazine or hypophthalin or hypoftalin or hydrazinophthalazine or idralazina or 1-hydrazinophthalazine or apressin or nepresol or apressoline or apresoline or apresolin or alphapress or alazine or idralazina or lopress or plethorit or praeparat).tw.<BR/>27 or/22-26<BR/>28 exp beta adrenergic receptor blocking agent/<BR/>29 (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol).tw.<BR/>30 (beta adj2 (adrenergic? or antagonist? or block$ or receptor?)).tw.<BR/>31 or/28-30<BR/>32 exp alpha adrenergic receptor blocking agent/<BR/>33 (alfuzosin or bunazosin or doxazosin or metazosin or neldazosin or prazosin or silodosin or tamsulosin or terazosin or tiodazosin or trimazosin).tw.<BR/>34 (andrenergic adj2 (alpha or antagonist?)).tw.<BR/>35 ((andrenergic or alpha or receptor?) adj2 block$).tw.<BR/>36 or/32-35<BR/>37 exp hypertension/<BR/>38 (hypertens$ or antihypertens$).tw.<BR/>39 ((high or elevat$ or rais$) adj2 blood pressure).tw.<BR/>40 or/37-39<BR/>41 double blind$.mp.<BR/>42 placebo$.tw.<BR/>43 blind$.tw.<BR/>44 or/41-43<BR/>45 (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)<BR/>46 Pregnancy/ or Hypertension, Pregnancy-Induced/ or Pregnancy Complications, Cardiovascular/ or exp Ocular Hypertension/<BR/>47 (pregnancy-induced or ocular hypertens$ or preeclampsia or pre-eclampsia).ti.<BR/>48 44 not (45 or 46 or 47)<BR/>49 (6 or 12 or 17 or 21 or 27 or 31 or 36) and 40 and 48<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-04-07 13:33:17 -0700" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-02-14 18:11:28 -0800" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-07 13:33:17 -0700" MODIFIED_BY="[Empty name]">
<P>Database: Cochrane Central Register of Controlled Trials on Wiley &lt;Issue 9, 2013&gt;<BR/>Search Date: 16 October 2013<BR/>--------------------------------------------------------------------------------<BR/>Database: Cochrane Central Register of Controlled Trials on Wiley &lt;Issue 9, 2013&gt;<BR/>Search Date: 16 October 2013<BR/>--------------------------------------------------------------------------------<BR/>ID Search<BR/>#1 MeSH descriptor: [Thiazides] explode all trees<BR/>#2 MeSH descriptor: [Sodium Chloride Symporter Inhibitors] explode all trees<BR/>#3 MeSH descriptor: [Sodium Potassium Chloride Symporter Inhibitors] explode all trees<BR/>#4 (loop or ceiling) next diuretic*:ti,ab<BR/>#5 (amiloride or benzothiadiazine or bendroflumethiazide or bumetanide or chlorothiazide or cyclopenthiazide or furosemide or hydrochlorothiazide or hydroflumethiazide or methyclothiazide or metolazone or polythiazide or trichlormethiazide or veratide or thiazide*):ti,ab<BR/>#6 (chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or oxodoline or thalitone or hygroton or indapamide or metindamide):ti,ab<BR/>#7 #1 or #2 or #3 or #4 or #5 or #6<BR/>#8 MeSH descriptor: [Angiotensin-Converting Enzyme Inhibitors] explode all trees<BR/>#9 "angiotensin converting enzyme" NEXT inhibit*:ti,ab<BR/>#10 ace near/3 inhibit*:ti,ab<BR/>#11 acei:ti,ab<BR/>#12 (alacepril or altiopril or ancovenin or benazepril or captopril or ceranapril or ceronapril or cilazapril or deacetylalacepril or delapril or derapril or enalapril or epicaptopril or fasidotril or fosinopril or foroxymithine or gemopatrilat or idapril or imidapril or indolapril or libenzapril or lisinopril or moexipril or moveltipril or omapatrilat or pentopril* or perindopril* or pivopril or quinapril* or ramipril* or rentiapril or saralasin or s nitrosocaptopril or spirapril* or temocapril* or teprotide or trandolapril* or utibapril* or zabicipril* or zofenopril*):ti,ab<BR/>#13 #8 or #9 or #10 or #11 or #12<BR/>#14 MeSH descriptor: [Angiotensin Receptor Antagonists] explode all trees<BR/>#15 angiotensin near/3 (receptor NEXT antagon* or receptor NEXT block*):ti,ab<BR/>#16 arb*:ti,ab<BR/>#17 (abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan or forasartan or irbesartan or losartan or milfasartan or olmesartan or saprisartan or tasosartan or telmisartan or valsartan or zolasartan):ti,ab<BR/>#18 #14 or #15 or #16 or #17<BR/>#19 MeSH descriptor: [Calcium Channel Blockers] explode all trees<BR/>#20 (amlodipine or amrinone or aranidipine or barnidipine or bencyclane or benidipine or bepridil or cilnidipine or cinnarizine or clentiazem or darodipine or diltiazem or efonidipine or elgodipine or etafenone or fantofarone or felodipine or fendiline or flunarizine or gallopamil or isradipine or lacidipine or lercanidipine or lidoflazine or lomerizine or manidipine or mibefradil or nicardipine or nifedipine or niguldipine or nilvadipine or nimodipine or nisoldipine or nitrendipine or perhexiline or prenylamine or semotiadil or terodiline or tiapamil or verapamil):ti,ab<BR/>#21 calcium near/2 (antagonist* or block* or inhibit*):ti,ab<BR/>#22 #19 or #20 or #21<BR/>#23 (methyldopa or alphamethyldopa or amodopa or dopamet or dopegyt or dopegit or dopegite or emdopa or hyperpax or hyperpaxa or methylpropionic acid or dopergit or meldopa or methyldopate or medopa or medomet or sembrina or aldomet or aldometil or aldomin or hydopa or methyldihydroxyphenylalanine or methyl dopa or mulfasin or presinol or presolisin or sedometil or sembrina or taquinil or dihydroxyphenylalanine or methylphenylalanine or methylalanine or alpha methyl dopa):ti,ab,kw<BR/>#24 (reserpine or serpentina or rauwolfia or serpasil):ti,ab,kw<BR/>#25 (clonidine or adesipress or arkamin or caprysin or catapres$ or catasan or chlofazolin or chlophazolin or clinidine or clofelin$ or clofenil or clomidine or clondine or clonistada or clonnirit or clophelin$ or dichlorophenylaminoimidazoline or dixarit or duraclon or gemiton or haemiton or hemiton or imidazoline or isoglaucon or klofelin or klofenil or m-5041t or normopresan or paracefan or st-155 or st 155 or tesno timelets):ti,ab,kw<BR/>#26 MeSH descriptor: [Hydralazine] explode all trees<BR/>#27 (hydralazin* or hydrallazin* or hydralizine or hydrazinophtalazine or hydrazinophthalazine or hydrazinophtalizine or dralzine or hydralacin or hydrolazine or hypophthalin or hypoftalin or hydrazinophthalazine or idralazina or 1-hydrazinophthalazine or apressin or nepresol or apressoline or apresoline or apresolin or alphapress or alazine or idralazina or lopress or plethorit or praeparat):ti,ab,kw<BR/>#28 #23 or #24 or #25 or #26 or #27<BR/>#29 MeSH descriptor: [Adrenergic beta-Antagonists] explode all trees<BR/>#30 (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol):ti,ab<BR/>#31 beta near/2 (adrenergic* or antagonist* or block* or receptor*):ti,ab<BR/>#32 #29 or #30 or #31<BR/>#33 MeSH descriptor: [Adrenergic alpha-Antagonists] explode all trees<BR/>#34 (alfuzosin or bunazosin or doxazosin or metazosin or neldazosin or prazosin or silodosin or tamsulosin or terazosin or tiodazosin or trimazosin):ti,ab<BR/>#35 adrenergic near/2 (alpha or antagonist*):ti,ab<BR/>#36 (adrenergic or alpha or receptor*) near/2 block*:ti,ab<BR/>#37 #33 or #34 or #35 or #36<BR/>#38 MeSH descriptor: [Hypertension] this term only<BR/>#39 hypertens*:ti,ab<BR/>#40 (elevat* or high* or raise*) near/2 "blood pressure":ti,ab<BR/>#41 #38 or #39 or #40<BR/>#42 (#7 or #13 or #18 or #22 or #28 or #32 or #37) and #41</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-10-17 17:51:44 -0700" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2013-10-17 17:51:39 -0700" MODIFIED_BY="[Empty name]">ClinicalTrials.gov</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-17 17:51:44 -0700" MODIFIED_BY="[Empty name]">
<P>Database: ClinicalTrials.gov<BR/>Search Date: 16 October 2013<BR/>--------------------------------------------------------------------------------<BR/>Search terms: randomized<BR/>Study type: Interventional Studies<BR/>Conditions: hypertension<BR/>Interventions: antihypertensive<BR/>Outcome Measures: blood pressure</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies (51 full text articles) included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;No studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;72 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7,781 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7,781 records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt; 16,325 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;No additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;7,709 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;21 full-text articles for 7 studies excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>